Escape from human immunodeficiency virus type 1 (HIV-1) entry inhibitors

Viruses

Volumn 4, Issue 12, 2012, Pages 3859-3911

  De Feo, Christopher J ^a   Weiss, Carol D ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

Entry inhibitor; Envelope glycoprotein; Fusion; HIV; Resistance; Virus entry

Indexed keywords

4 [1 [(2,4 DIMETHYL 3 PYRIDINYL)CARBONYL] 4 METHYL 4 PIPERIDINYL] 2 METHYL 1 [1 [4 (TRIFLUOROMETHYL)PHENYL]ETHYL]PIPERAZINE; APLAVIROC; CD4 ANTIGEN; CELL RECEPTOR; CENICRIVIROC; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; CHEMOKINE RECEPTOR CXCR5; CHEMOKINE RECEPTOR CXCR5 ANTAGONIST; DP 107; ENFUVIRTIDE; GLYCOPROTEIN; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; HR FUSION INHIBITOR; HR1 PEPTIDE INHIBITOR; HR1 PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IBALIZUMAB; IZN 36; MARAVIROC; MUTANT PROTEIN; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; PROTEIN INHIBITOR; SJ 2176; T 134; UNCLASSIFIED DRUG; UNINDEXED DRUG; VICRIVIROC; VIRUS ENVELOPE PROTEIN;

ANTIVIRAL RESISTANCE; DRUG DESIGN; DRUG TARGETING; ENVELOPE GENE; HOST CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; NONHUMAN; REVIEW; VIRUS ENTRY; VIRUS ENVELOPE; VIRUS MUTATION; VIRUS REPLICATION;

ADAPTATION, BIOLOGICAL; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV FUSION INHIBITORS; HIV-1; HUMANS; MUTANT PROTEINS; SELECTION, GENETIC;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84871904965     PISSN: 19994915     EISSN: None     Source Type: Journal    
DOI: 10.3390/v4123859     Document Type: Review

References (352)

1. Arts, E.J.; Hazuda, D.J. HIV-1 Antiretroviral drug therapy. Cold Spring Harb. Perspect. Med. 2012, 2, a007161.
2. Antiretroviral drugs used in the treatment of HIV infection. Available online: http://www.fda.gov/ forconsumers/byaudience/forpatientadvocates/hivandaidsactivities/ucm118915.htm (accessed on 6 November 2012).
3. Palella, F.J., Jr.; Delaney, K.M.; Moorman, A.C.; Loveless, M.O.; Fuhrer, J.; Satten, G.A.; Aschman, D.J.; Holmberg, S.D. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. New Engl. J. Med. 1998, 338, 853-860.
4. Tsibris, A.M.; Hirsch, M.S. Antiretroviral therapy in the clinic. J. Virol. 2010, 84, 5458-5464.
5. Ho, D.D.; Neumann, A.U.; Perelson, A.S.; Chen, W.; Leonard, J.M.; Markowitz, M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995, 373, 123-126.
6. Wei, X.; Ghosh, S.K.; Taylor, M.E.; Johnson, V.A.; Emini, E.A.; Deutsch, P.; Lifson, J.D.; Bonhoeffer, S.; Nowak, M.A.; Hahn, B.H.; et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995, 373, 117-122.
7. Tilton, J.C.; Doms, R.W. Entry inhibitors in the treatment of HIV-1 infection. Antivir. Res. 2010, 85, 91-100.
8. Eggink, D.; Berkhout, B.; Sanders, R.W. Inhibition of HIV-1 by fusion inhibitors. Curr. Pharmaceut. Des. 2010, 16, 3716-3728.
9. Kuritzkes, D.R. HIV-1 entry inhibitors: An overview. Curr. Opin. HIV AIDS 2009, 4, 82-87.
10. Cai, L.; Jiang, S. Development of peptide and small-molecule HIV-1 fusion inhibitors that target gp41. ChemMedChem 2010, 5, 1813-1824.
11. Ugolini, S.; Mondor, I.; Sattentau, Q.J. HIV-1 attachment: Another look. Trends Microbiol. 1999, 7, 144-149.
12. Klatzmann, D.; Champagne, E.; Chamaret, S.; Gruest, J.; Guetard, D.; Hercend, T.; Gluckman, J.C.; Montagnier, L. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature 1984, 312, 767-768.
13. Dalgleish, A.G.; Beverley, P.C.; Clapham, P.R.; Crawford, D.H.; Greaves, M.F.; Weiss, R.A. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 1984, 312, 763-767.
14. McDougal, J.S.; Kennedy, M.S.; Sligh, J.M.; Cort, S.P.; Mawle, A.; Nicholson, J.K. Binding of HTLV-III/LAV to T4+ T cells by a complex of the 110K viral protein and the T4 molecule. Science 1986, 231, 382-385.
15. Maddon, P.J.; Dalgleish, A.G.; McDougal, J.S.; Clapham, P.R.; Weiss, R.A.; Axel, R. The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell 1986, 47, 333-348.
16. Feng, Y.; Broder, C.C.; Kennedy, P.E.; Berger, E.A. HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996, 272, 872-877.
17. Alkhatib, G.; Combadiere, C.; Broder, C.C.; Feng, Y.; Kennedy, P.E.; Murphy, P.M.; Berger, E.A. CC CKR5: A RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996, 272, 1955-1958.
18. Choe, H.; Farzan, M.; Sun, Y.; Sullivan, N.; Rollins, B.; Ponath, P.D.; Wu, L.; Mackay, C.R.; LaRosa, G.; Newman, W.; et al. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996, 85, 1135-1148.
19. Deng, H.; Liu, R.; Ellmeier, W.; Choe, S.; Unutmaz, D.; Burkhart, M.; di Marzio, P.; Marmon, S.; Sutton, R.E.; Hill, C.M.; et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996, 381, 661-666.
20. Doranz, B.J.; Rucker, J.; Yi, Y.; Smyth, R.J.; Samson, M.; Peiper, S.C.; Parmentier, M.; Collman, R.G.; Doms, R.W. A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 1996, 85, 1149-1158.
21. Dragic, T.; Litwin, V.; Allaway, G.P.; Martin, S.R.; Huang, Y.; Nagashima, K.A.; Cayanan, C.; Maddon, P.J.; Koup, R.A.; Moore, J.P.; et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996, 381, 667-673.
22. Berger, E.A.; Murphy, P.M.; Farber, J.M. Chemokine receptors as HIV-1 coreceptors: Roles in viral entry, tropism, and disease. Annu. Rev. Immunol. 1999, 17, 657-700.
23. Zaitseva, M.; Peden, K.; Golding, H. HIV coreceptors: Role of structure, posttranslational modifications, and internalization in viral-cell fusion and as targets for entry inhibitors. Biochim. Biophys. Acta 2003, 1614, 51-61.
24. Melikyan, G.B. Membrane fusion mediated by human immunodeficiency virus envelope glycoprotein. Curr. Top. Membr. 2011, 68, 81-106.
25. Eckert, D.M.; Kim, P.S. Mechanisms of viral membrane fusion and its inhibition. Annu. Rev. Biochem. 2001, 70, 777-810.
26. Kwong, P.D.; Wyatt, R.; Robinson, J.; Sweet, R.W.; Sodroski, J.; Hendrickson, W.A. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998, 393, 648-659.
27. Moore, J.P.; McKeating, J.A.; Weiss, R.A.; Sattentau, Q.J. Dissociation of gp120 from HIV-1 virions induced by soluble CD4. Science 1990, 250, 1139-1142.
28. Sattentau, Q.J.; Moore, J.P. Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding. J. Exp. Med. 1991, 174, 407-415.
29. Wu, L.; Gerard, N.P.; Wyatt, R.; Choe, H.; Parolin, C.; Ruffing, N.; Borsetti, A.; Cardoso, A.A.; Desjardin, E.; Newman, W.; et al. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature 1996, 384, 179-183.
30. Trkola, A.; Dragic, T.; Arthos, J.; Binley, J.M.; Olson, W.C.; Allaway, G.P.; Cheng-Mayer, C.; Robinson, J.; Maddon, P.J.; Moore, J.P. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature 1996, 384, 184-187.
31. Thali, M.; Moore, J.P.; Furman, C.; Charles, M.; Ho, D.D.; Robinson, J.; Sodroski, J. Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J. Virol. 1993, 67, 3978-3988.
32. Chen, B.; Vogan, E.M.; Gong, H.; Skehel, J.J.; Wiley, D.C.; Harrison, S.C. Structure of an unliganded simian immunodeficiency virus gp120 core. Nature 2005, 433, 834-841.
33. Liu, J.; Bartesaghi, A.; Borgnia, M.J.; Sapiro, G.; Subramaniam, S. Molecular architecture of native HIV-1 gp120 trimers. Nature 2008, 455, 109-113.
34. Myszka, D.G.; Sweet, R.W.; Hensley, P.; Brigham-Burke, M.; Kwong, P.D.; Hendrickson, W.A.; Wyatt, R.; Sodroski, J.; Doyle, M.L. Energetics of the HIV gp120-CD4 binding reaction. Proc. Natl. Acad. Sci. U. S. A. 2000, 97, 9026-9031.
35. Kwon, Y.D.; Finzi, A.; Wu, X.; Dogo-Isonagie, C.; Lee, L.K.; Moore, L.R.; Schmidt, S.D.; Stuckey, J.; Yang, Y.; Zhou, T.; et al. Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops. Proc. Natl. Acad. Sci. U. S. A. 2012, 109, 5663-5668.
36. Yuan, W.; Bazick, J.; Sodroski, J. Characterization of the multiple conformational States of free monomeric and trimeric human immunodeficiency virus envelope glycoproteins after fixation by cross-linker. J. Virol. 2006, 80, 6725-6737.
37. Kong, L.; Huang, C.C.; Coales, S.J.; Molnar, K.S.; Skinner, J.; Hamuro, Y.; Kwong, P.D. Local conformational stability of HIV-1 gp120 in unliganded and CD4-bound states as defined by amide hydrogen/deuterium exchange. J. Virol. 2010, 84, 10311-10321.
38. Kwong, P.D.; Doyle, M.L.; Casper, D.J.; Cicala, C.; Leavitt, S.A.; Majeed, S.; Steenbeke, T.D.; Venturi, M.; Chaiken, I.; Fung, M.; et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 2002, 420, 678-682.
39. Xiang, S.H.; Kwong, P.D.; Gupta, R.; Rizzuto, C.D.; Casper, D.J.; Wyatt, R.; Wang, L.; Hendrickson, W.A.; Doyle, M.L.; Sodroski, J. Mutagenic stabilization and/or disruption of a CD4-bound state reveals distinct conformations of the human immunodeficiency virus type 1 gp120 envelope glycoprotein. J. Virol. 2002, 76, 9888-9899.
40. Pancera, M.; Majeed, S.; Ban, Y.E.; Chen, L.; Huang, C.C.; Kong, L.; Kwon, Y.D.; Stuckey, J.; Zhou, T.; Robinson, J.E.; et al. Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility. Proc. Natl. Acad. Sci. U. S. A. 2010, 107, 1166-1171.
41. Huang, C.C.; Tang, M.; Zhang, M.Y.; Majeed, S.; Montabana, E.; Stanfield, R.L.; Dimitrov, D.S.; Korber, B.; Sodroski, J.; Wilson, I.A.; et al. Structure of a V3-containing HIV-1 gp120 core. Science 2005, 310, 1025-1028.
42. Huang, C.C.; Lam, S.N.; Acharya, P.; Tang, M.; Xiang, S.H.; Hussan, S.S.; Stanfield, R.L.; Robinson, J.; Sodroski, J.; Wilson, I.A.; et al. Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4. Science 2007, 317, 1930-1934.
43. Hussey, R.E.; Richardson, N.E.; Kowalski, M.; Brown, N.R.; Chang, H.C.; Siliciano, R.F.; Dorfman, T.; Walker, B.; Sodroski, J.; Reinherz, E.L. A soluble CD4 protein selectively inhibits HIV replication and syncytium formation. Nature 1988, 331, 78-81.
44. Deen, K.C.; McDougal, J.S.; Inacker, R.; Folena-Wasserman, G.; Arthos, J.; Rosenberg, J.; Maddon, P.J.; Axel, R.; Sweet, R.W. A soluble form of CD4 (T4) protein inhibits AIDS virus infection. Nature 1988, 331, 82-84.
45. Fisher, R.A.; Bertonis, J.M.; Meier, W.; Johnson, V.A.; Costopoulos, D.S.; Liu, T.; Tizard, R.; Walker, B.D.; Hirsch, M.S.; Schooley, R.T.; et al. HIV infection is blocked in vitro by recombinant soluble CD4. Nature 1988, 331, 76-78.
46. Clapham, P.R.; Weber, J.N.; Whitby, D.; McIntosh, K.; Dalgleish, A.G.; Maddon, P.J.; Deen, K.C.; Sweet, R.W.; Weiss, R.A. Soluble CD4 blocks the infectivity of diverse strains of HIV and SIV for T cells and monocytes but not for brain and muscle cells. Nature 1989, 337, 368-370.
47. Allan, J.S.; Strauss, J.; Buck, D.W. Enhancement of SIV infection with soluble receptor molecules. Science 1990, 247, 1084-1088.
48. Clapham, P.R.; McKnight, A.; Weiss, R.A. Human immunodeficiency virus type 2 infection and fusion of CD4-negative human cell lines: Induction and enhancement by soluble CD4. J. Virol. 1992, 66, 3531-3537.
49. Allan, J.S.; Whitehead, E.M.; Strout, K.; Short, M.; Kanda, P.; Hart, T.K.; Bugelski, P.J. Strong association of simian immunodeficiency virus (SIVagm) envelope glycoprotein heterodimers: Possible role in receptor-mediated activation. AIDS Res. Hum. Retrovir. 1992, 8, 2011-2020.
50. Sullivan, N.; Sun, Y.; Li, J.; Hofmann, W.; Sodroski, J. Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates. J. Virol. 1995, 69, 4413-4422.
51. Schutten, M.; Andeweg, A.C.; Bosch, M.L.; Osterhaus, A.D. Enhancement of infectivity of a non-syncytium inducing HIV-1 by sCD4 and by human antibodies that neutralize syncytium inducing HIV-1. Scand. J. Immunol. 1995, 41, 18-22.
52. Daar, E.S.; Li, X.L.; Moudgil, T.; Ho, D.D. High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. Proc. Natl. Acad. Sci. U. S. A. 1990, 87, 6574-6578.
53. Brighty, D.W.; Rosenberg, M.; Chen, I.S.; Ivey-Hoyle, M. Envelope proteins from clinical isolates of human immunodeficiency virus type 1 that are refractory to neutralization by soluble CD4 possess high affinity for the CD4 receptor. Proc. Natl. Acad. Sci. U. S. A. 1991, 88, 7802-7805.
54. Moore, J.P.; McKeating, J.A.; Huang, Y.X.; Ashkenazi, A.; Ho, D.D. Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates. J. Virol. 1992, 66, 235-243.
55. Turner, S.; Tizard, R.; DeMarinis, J.; Pepinsky, R.B.; Zullo, J.; Schooley, R.; Fisher, R. Resistance of primary isolates of human immunodeficiency virus type 1 to neutralization by soluble CD4 is not due to lower affinity with the viral envelope glycoprotein gp120. Proc. Natl. Acad. Sci. U. S. A. 1992, 89, 1335-1339.
56. Orloff, S.L.; Kennedy, M.S.; Belperron, A.A.; Maddon, P.J.; McDougal, J.S. Two mechanisms of soluble CD4 (sCD4)-mediated inhibition of human immunodeficiency virus type 1 (HIV-1) infectivity and their relation to primary HIV-1 isolates with reduced sensitivity to sCD4. J. Virol. 1993, 67, 1461-1471.
57. Groenink, M.; Moore, J.P.; Broersen, S.; Schuitemaker, H. Equal levels of gp120 retention and neutralization resistance of phenotypically distinct primary human immunodeficiency virus type 1 variants upon soluble CD4 treatment. J. Virol. 1995, 69, 523-527.
58. Moore, J.P.; McKeating, J.A.; Norton, W.A.; Sattentau, Q.J. Direct measurement of soluble CD4 binding to human immunodeficiency virus type 1 virions: gp120 dissociation and its implications for virus-cell binding and fusion reactions and their neutralization by soluble CD4. J. Virol. 1991, 65, 1133-1140.
59. Hart, T.K.; Kirsh, R.; Ellens, H.; Sweet, R.W.; Lambert, D.M.; Petteway, S.R., Jr.; Leary, J.; Bugelski, P.J. Binding of soluble CD4 proteins to human immunodeficiency virus type 1 and infected cells induces release of envelope glycoprotein gp120. Proc. Natl. Acad. Sci. U. S. A. 1991, 88, 2189-2193.
60. Vita, C.; Drakopoulou, E.; Vizzavona, J.; Rochette, S.; Martin, L.; Menez, A.; Roumestand, C.; Yang, Y.S.; Ylisastigui, L.; Benjouad, A.; et al. Rational engineering of a miniprotein that reproduces the core of the CD4 site interacting with HIV-1 envelope glycoprotein. Proc. Natl. Acad. Sci. U. S. A. 1999, 96, 13091-13096.
61. Martin, L.; Stricher, F.; Misse, D.; Sironi, F.; Pugniere, M.; Barthe, P.; Prado-Gotor, R.; Freulon, I.; Magne, X.; Roumestand, C.; et al. Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes. Nat. Biotechnol. 2003, 21, 71-76.
62. Stricher, F.; Huang, C.C.; Descours, A.; Duquesnoy, S.; Combes, O.; Decker, J.M.; Kwon, Y.D.; Lusso, P.; Shaw, G.M.; Vita, C.; et al. Combinatorial optimization of a CD4-mimetic miniprotein and cocrystal structures with HIV-1 gp120 envelope glycoprotein. J. Mol. Biol. 2008, 382, 510-524.
63. Grupping, K.; Selhorst, P.; Michiels, J.; Vereecken, K.; Heyndrickx, L.; Kessler, P.; Vanham, G.; Martin, L.; Arien, K.K. MiniCD4 protein resistance mutations affect binding to the HIV-1 gp120 CD4 binding site and decrease entry efficiency. Retrovirology 2012, 9, 36.
64. Yoshimura, K.; Harada, S.; Shibata, J.; Hatada, M.; Yamada, Y.; Ochiai, C.; Tamamura, H.; Matsushita, S. Enhanced exposure of human immunodeficiency virus type 1 primary isolate neutralization epitopes through binding of CD4 mimetic compounds. J. Virol. 2010, 84, 7558-7568.
65. McKeating, J.; Balfe, P.; Clapham, P.; Weiss, R.A. Recombinant CD4-selected human immunodeficiency virus type 1 variants with reduced gp120 affinity for CD4 and increased cell fusion capacity. J. Virol. 1991, 65, 4777-4785.
66. McKeating, J.A.; Bennett, J.; Zolla-Pazner, S.; Schutten, M.; Ashelford, S.; Brown, A.L.; Balfe, P. Resistance of a human serum-selected human immunodeficiency virus type 1 escape mutant to neutralization by CD4 binding site monoclonal antibodies is conferred by a single amino acid change in gp120. J. Virol. 1993, 67, 5216-5225.
67. Zhao, Q.; Ma, L.; Jiang, S.; Lu, H.; Liu, S.; He, Y.; Strick, N.; Neamati, N.; Debnath, A.K. Identification of N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4. Virology 2005, 339, 213-225.
68. Schon, A.; Madani, N.; Klein, J.C.; Hubicki, A.; Ng, D.; Yang, X.; Smith, A.B., 3rd; Sodroski, J.; Freire, E. Thermodynamics of binding of a low-molecular-weight CD4 mimetic to HIV-1 gp120. Biochemistry 2006, 45, 10973-10980.
69. Madani, N.; Schon, A.; Princiotto, A.M.; Lalonde, J.M.; Courter, J.R.; Soeta, T.; Ng, D.; Wang, L.; Brower, E.T.; Xiang, S.H.; et al. Small-molecule CD4 mimics interact with a highly conserved pocket on HIV-1 gp120. Structure 2008, 16, 1689-1701.
70. Yoshimura, K.; Harada, S.; Shibata, J.; Hatada, M.; Yamada, Y.; Ochiai, C.; Tamamura, H.; Matsushita, S. Enhanced exposure of human immunodeficiency virus type 1 primary isolate neutralization epitopes through binding of CD4 mimetic compounds. J. Virol. 84, 7558-7568.
71. Yamada, Y.; Ochiai, C.; Yoshimura, K.; Tanaka, T.; Ohashi, N.; Narumi, T.; Nomura, W.; Harada, S.; Matsushita, S.; Tamamura, H. CD4 mimics targeting the mechanism of HIV entry. Bioorg. Med. Chem. Lett. 2010, 20, 354-358.
72. Haim, H.; Si, Z.; Madani, N.; Wang, L.; Courter, J.R.; Princiotto, A.; Kassa, A.; DeGrace, M.; McGee-Estrada, K.; Mefford, M.; et al. Soluble CD4 and CD4-mimetic compounds inhibit HIV-1 infection by induction of a short-lived activated state. PLoS Pathog. 2009, 5, e1000360.
73. Lin, P.F.; Blair, W.; Wang, T.; Spicer, T.; Guo, Q.; Zhou, N.; Gong, Y.F.; Wang, H.G.; Rose, R.; Yamanaka, G.; et al. A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proc. Natl. Acad. Sci. U. S. A. 2003, 100, 11013-11018.
74. Wang, T.; Zhang, Z.; Wallace, O.B.; Deshpande, M.; Fang, H.; Yang, Z.; Zadjura, L.M.; Tweedie, D.L.; Huang, S.; Zhao, F.; et al. Discovery of 4-benzoyl-1-[(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2-(R)-methylpiperazine (BMS-378806): A novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions. J. Med. Chem. 2003, 46, 4236-4239.
75. Madani, N.; Perdigoto, A.L.; Srinivasan, K.; Cox, J.M.; Chruma, J.J.; LaLonde, J.; Head, M.; Smith, A.B., 3rd; Sodroski, J.G. Localized changes in the gp120 envelope glycoprotein confer resistance to human immunodeficiency virus entry inhibitors BMS-806 and #155. J. Virol. 2004, 78, 3742-3752.
76. Zhou, N.; Nowicka-Sans, B.; Zhang, S.; Fan, L.; Fang, J.; Fang, H.; Gong, Y.F.; Eggers, B.; Langley, D.R.; Wang, T.; et al. In vivo patterns of resistance to the HIV attachment inhibitor BMS-488043. Antimicrob. Agents Chemother. 2011, 55, 729-737.
77. Guo, Q.; Ho, H.T.; Dicker, I.; Fan, L.; Zhou, N.; Friborg, J.; Wang, T.; McAuliffe, B.V.; Wang, H.G.; Rose, R.E.; et al. Biochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactions. J. Virol. 2003, 77, 10528-10536.
78. Si, Z.; Madani, N.; Cox, J.M.; Chruma, J.J.; Klein, J.C.; Schon, A.; Phan, N.; Wang, L.; Biorn, A.C.; Cocklin, S.; et al. Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins. Proc. Natl. Acad. Sci. U. S. A. 2004, 101, 5036-5041.
79. Ho, H.T.; Fan, L.; Nowicka-Sans, B.; McAuliffe, B.; Li, C.B.; Yamanaka, G.; Zhou, N.; Fang, H.; Dicker, I.; Dalterio, R.; et al. Envelope conformational changes induced by human immunodeficiency virus type 1 attachment inhibitors prevent CD4 binding and downstream entry events. J. Virol. 2006, 80, 4017-4025.
80. Zhou, N.; Fan, L.; Ho, H.T.; Nowicka-Sans, B.; Sun, Y.; Zhu, Y.; Hu, Y.; McAuliffe, B.; Rose, B.; Fang, H.; et al. Increased sensitivity of HIV variants selected by attachment inhibitors to broadly neutralizing antibodies. Virology 2010, 402, 256-261.
81. Vermeire, K.; Zhang, Y.; Princen, K.; Hatse, S.; Samala, M.F.; Dey, K.; Choi, H.J.; Ahn, Y.; Sodoma, A.; Snoeck, R.; et al. CADA inhibits human immunodeficiency virus and human herpesvirus 7 replication by down-modulation of the cellular CD4 receptor. Virology 2002, 302, 342-353.
82. Vermeire, K.; Schols, D. Cyclotriazadisulfonamides: Promising new CD4-targeted anti-HIV drugs. J. Antimicrob. Chemother. 2005, 56, 270-272.
83. Vermeire, K.; Bell, T.W.; Choi, H.J.; Jin, Q.; Samala, M.F.; Sodoma, A.; de Clercq, E.; Schols, D. The anti-HIV potency of cyclotriazadisulfonamide analogs is directly correlated with their ability to down-modulate the CD4 receptor. Mol. Pharmacol. 2003, 63, 203-210.
84. Kabat, D.; Kozak, S.L.; Wehrly, K.; Chesebro, B. Differences in CD4 dependence for infectivity of laboratory-adapted and primary patient isolates of human immunodeficiency virus type 1. J. Virol. 1994, 68, 2570-2577.
85. Vermeire, K.; Van Laethem, K.; Janssens, W.; Bell, T.W.; Schols, D. Human immunodeficiency virus type 1 escape from cyclotriazadisulfonamide-induced CD4-targeted entry inhibition is associated with increased neutralizing antibody susceptibility. J. Virol. 2009, 83, 9577-9583.
86. Vermeire, K.; Brouwers, J.; Van Herrewege, Y.; Le Grand, R.; Vanham, G.; Augustijns, P.; Bell, T.W.; Schols, D. CADA, a potential anti-HIV microbicide that specifically targets the cellular CD4 receptor. Curr. HIV Res. 2008, 6, 246-256.
87. Reimann, K.A.; Lin, W.; Bixler, S.; Browning, B.; Ehrenfels, B.N.; Lucci, J.; Miatkowski, K.; Olson, D.; Parish, T.H.; Rosa, M.D.; et al. A humanized form of a CD4-specific monoclonal antibody exhibits decreased antigenicity and prolonged plasma half-life in rhesus monkeys while retaining its unique biological and antiviral properties. AIDS Res. Hum. Retrovir. 1997, 13, 933-943.
88. Burkly, L.C.; Olson, D.; Shapiro, R.; Winkler, G.; Rosa, J.J.; Thomas, D.W.; Williams, C.; Chisholm, P. Inhibition of HIV infection by a novel CD4 domain 2-specific monoclonal antibody. Dissecting the basis for its inhibitory effect on HIV-induced cell fusion. J. Immunol. 1992, 149, 1779-1787.
89. Moore, J.P.; Sattentau, Q.J.; Klasse, P.J.; Burkly, L.C. A monoclonal antibody to CD4 domain 2 blocks soluble CD4-induced conformational changes in the envelope glycoproteins of human immunodeficiency virus type 1 (HIV-1) and HIV-1 infection of CD4+ cells. J. Virol. 1992, 66, 4784-4793.
90. Reimann, K.A.; Burkly, L.C.; Burrus, B.; Waite, B.C.; Lord, C.I.; Letvin, N.L. In vivo administration to rhesus monkeys of a CD4-specific monoclonal antibody capable of blocking AIDS virus replication. AIDS Res. Hum. Retrovir. 1993, 9, 199-207.
91. Boon, L.; Holland, B.; Gordon, W.; Liu, P.; Shiau, F.; Shanahan, W.; Reimann, K.A.; Fung, M. Development of anti-CD4 MAb hu5A8 for treatment of HIV-1 infection: Preclinical assessment in non-human primates. Toxicology 2002, 172, 191-203.
92. Freeman, M.M.; Seaman, M.S.; Rits-Volloch, S.; Hong, X.; Kao, C.Y.; Ho, D.D.; Chen, B. Crystal structure of HIV-1 primary receptor CD4 in complex with a potent antiviral antibody. Structure 2010, 18, 1632-1641.
93. Reimann, K.A.; Khunkhun, R.; Lin, W.; Gordon, W.; Fung, M. A humanized, nondepleting anti-CD4 antibody that blocks virus entry inhibits virus replication in rhesus monkeys chronically infected with simian immunodeficiency virus. AIDS Res. Hum. Retrovir. 2002, 18, 747-755.
94. Jacobson, J.M.; Kuritzkes, D.R.; Godofsky, E.; DeJesus, E.; Larson, J.A.; Weinheimer, S.P.; Lewis, S.T. Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults. Antimicrob. Agents Chemother. 2009, 53, 450-457.
95. Kuritzkes, D.R.; Jacobson, J.; Powderly, W.G.; Godofsky, E.; DeJesus, E.; Haas, F.; Reimann, K.A.; Larson, J.L.; Yarbough, P.O.; Curt, V.; et al. Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1. J. Infect. Dis. 2004, 189, 286-291.
96. Toma, J.; Weinheimer, S.P.; Stawiski, E.; Whitcomb, J.M.; Lewis, S.T.; Petropoulos, C.J.; Huang, W. Loss of asparagine-linked glycosylation sites in variable region 5 of human immunodeficiency virus type 1 envelope is associated with resistance to CD4 antibody ibalizumab. J. Virol. 2011, 85, 3872-3880.
97. Tran, E.E.; Borgnia, M.J.; Kuybeda, O.; Schauder, D.M.; Bartesaghi, A.; Frank, G.A.; Sapiro, G.; Milne, J.L.; Subramaniam, S. Structural mechanism of trimeric HIV-1 envelope glycoprotein activation. PLoS Pathog. 2012, 8, e1002797.
98. Gallo, S.A.; Finnegan, C.M.; Viard, M.; Raviv, Y.; Dimitrov, A.; Rawat, S.S.; Puri, A.; Durell, S.; Blumenthal, R. The HIV Env-mediated fusion reaction. Biochim. Biophys. Acta 2003, 1614, 36-50.
99. Berson, J.F.; Long, D.; Doranz, B.J.; Rucker, J.; Jirik, F.R.; Doms, R.W. A seven-transmembrane domain receptor involved in fusion and entry of T-cell-tropic human immunodeficiency virus type 1 strains. J. Virol. 1996, 70, 6288-6295.
100. Cocchi, F.; DeVico, A.L.; Garzino-Demo, A.; Arya, S.K.; Gallo, R.C.; Lusso, P. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995, 270, 1811-1815.
101. Bleul, C.C.; Farzan, M.; Choe, H.; Parolin, C.; Clark-Lewis, I.; Sodroski, J.; Springer, T.A. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature 1996, 382, 829-833.
102. Oberlin, E.; Amara, A.; Bachelerie, F.; Bessia, C.; Virelizier, J.L.; Arenzana-Seisdedos, F.; Schwartz, O.; Heard, J.M.; Clark-Lewis, I.; Legler, D.F.; et al. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature 1996, 382, 833-835.
103. Rizzuto, C.D.; Wyatt, R.; Hernandez-Ramos, N.; Sun, Y.; Kwong, P.D.; Hendrickson, W.A.; Sodroski, J. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science 1998, 280, 1949-1953.
104. Rizzuto, C.; Sodroski, J. Fine definition of a conserved CCR5-binding region on the human immunodeficiency virus type 1 glycoprotein 120. AIDS Res. Hum. Retrovir. 2000, 16, 741-749.
105. Doranz, B.J.; Lu, Z.H.; Rucker, J.; Zhang, T.Y.; Sharron, M.; Cen, Y.H.; Wang, Z.X.; Guo, H.H.; Du, J.G.; Accavitti, M.A.; et al. Two distinct CCR5 domains can mediate coreceptor usage by human immunodeficiency virus type 1. J. Virol. 1997, 71, 6305-6314.
106. Farzan, M.; Choe, H.; Vaca, L.; Martin, K.; Sun, Y.; Desjardins, E.; Ruffing, N.; Wu, L.; Wyatt, R.; Gerard, N.; et al. A tyrosine-rich region in the N terminus of CCR5 is important for human immunodeficiency virus type 1 entry and mediates an association between gp120 and CCR5. J. Virol. 1998, 72, 1160-1164.
107. Kajumo, F.; Thompson, D.A.; Guo, Y.; Dragic, T. Entry of R5X4 and X4 human immunodeficiency virus type 1 strains is mediated by negatively charged and tyrosine residues in the amino-terminal domain and the second extracellular loop of CXCR4. Virology 2000, 271, 240-247.
108. Cormier, E.G.; Tran, D.N.; Yukhayeva, L.; Olson, W.C.; Dragic, T. Mapping the determinants of the CCR5 amino-terminal sulfopeptide interaction with soluble human immunodeficiency virus type 1 gp120-CD4 complexes. J. Virol. 2001, 75, 5541-5549.
109. Cormier, E.G.; Dragic, T. The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor. J. Virol. 2002, 76, 8953-8957.
110. Nolan, K.M.; Jordan, A.P.; Hoxie, J.A. Effects of partial deletions within the human immunodeficiency virus type 1 V3 loop on coreceptor tropism and sensitivity to entry inhibitors. J. Virol. 2008, 82, 664-673.
111. Lee, B.; Sharron, M.; Blanpain, C.; Doranz, B.J.; Vakili, J.; Setoh, P.; Berg, E.; Liu, G.; Guy, H.R.; Durell, S.R.; et al. Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function. J. Biol. Chem. 1999, 274, 9617-9626.
112. Farzan, M.; Mirzabekov, T.; Kolchinsky, P.; Wyatt, R.; Cayabyab, M.; Gerard, N.P.; Gerard, C.; Sodroski, J.; Choe, H. Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry. Cell 1999, 96, 667-676.
113. Arenzana-Seisdedos, F.; Virelizier, J.L.; Rousset, D.; Clark-Lewis, I.; Loetscher, P.; Moser, B.; Baggiolini, M. HIV blocked by chemokine antagonist. Nature 1996, 383, 400.
114. Amara, A.; Gall, S.L.; Schwartz, O.; Salamero, J.; Montes, M.; Loetscher, P.; Baggiolini, M.; Virelizier, J.L.; Arenzana-Seisdedos, F. HIV coreceptor downregulation as antiviral principle: SDF-1alpha-dependent internalization of the chemokine receptor CXCR4 contributes to inhibition of HIV replication. J. Exp. Med. 1997, 186, 139-146.
115. Signoret, N.; Oldridge, J.; Pelchen-Matthews, A.; Klasse, P.J.; Tran, T.; Brass, L.F.; Rosenkilde, M.M.; Schwartz, T.W.; Holmes, W.; Dallas, W.; et al. Phorbol esters and SDF-1 induce rapid endocytosis and down modulation of the chemokine receptor CXCR4. J. Cell Biol. 1997, 139, 651-664.
116. Simmons, G.; Clapham, P.R.; Picard, L.; Offord, R.E.; Rosenkilde, M.M.; Schwartz, T.W.; Buser, R.; Wells, T.N.; Proudfoot, A.E. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science 1997, 276, 276-279.
117. Mack, M.; Luckow, B.; Nelson, P.J.; Cihak, J.; Simmons, G.; Clapham, P.R.; Signoret, N.; Marsh, M.; Stangassinger, M.; Borlat, F.; et al. Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: A novel inhibitory mechanism of HIV infectivity. J. Exp. Med. 1998, 187, 1215-1224.
118. Pastore, C.; Picchio, G.R.; Galimi, F.; Fish, R.; Hartley, O.; Offord, R.E.; Mosier, D.E. Two mechanisms for human immunodeficiency virus type 1 inhibition by N-terminal modifications of RANTES. Antimicrob. Agents Chemother. 2003, 47, 509-517.
119. Baba, M.; Nishimura, O.; Kanzaki, N.; Okamoto, M.; Sawada, H.; Iizawa, Y.; Shiraishi, M.; Aramaki, Y.; Okonogi, K.; Ogawa, Y.; et al. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc. Natl. Acad. Sci. U. S. A. 1999, 96, 5698-5703.
120. Dragic, T.; Trkola, A.; Thompson, D.A.; Cormier, E.G.; Kajumo, F.A.; Maxwell, E.; Lin, S.W.; Ying, W.; Smith, S.O.; Sakmar, T.P.; et al. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc. Natl. Acad. Sci. U. S. A. 2000, 97, 5639-5644.
121. Strizki, J.M.; Xu, S.; Wagner, N.E.; Wojcik, L.; Liu, J.; Hou, Y.; Endres, M.; Palani, A.; Shapiro, S.; Clader, J.W.; et al. SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo. Proc. Natl. Acad. Sci. U. S. A. 2001, 98, 12718-12723.
122. Kazmierski, W.; Bifulco, N.; Yang, H.; Boone, L.; DeAnda, F.; Watson, C.; Kenakin, T. Recent progress in discovery of small-molecule CCR5 chemokine receptor ligands as HIV-1 inhibitors. Bioorg. Med. Chem. 2003, 11, 2663-2676.
123. Tsamis, F.; Gavrilov, S.; Kajumo, F.; Seibert, C.; Kuhmann, S.; Ketas, T.; Trkola, A.; Palani, A.; Clader, J.W.; Tagat, J.R.; et al. Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry. J. Virol. 2003, 77, 5201-5208.
124. Billick, E.; Seibert, C.; Pugach, P.; Ketas, T.; Trkola, A.; Endres, M.J.; Murgolo, N.J.; Coates, E.; Reyes, G.R.; Baroudy, B.M.; et al. The differential sensitivity of human and rhesus macaque CCR5 to small-molecule inhibitors of human immunodeficiency virus type 1 entry is explained by a single amino acid difference and suggests a mechanism of action for these inhibitors. J. Virol. 2004, 78, 4134-4144.
125. Maeda, K.; Nakata, H.; Koh, Y.; Miyakawa, T.; Ogata, H.; Takaoka, Y.; Shibayama, S.; Sagawa, K.; Fukushima, D.; Moravek, J.; et al. Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro. J. Virol. 2004, 78, 8654-8662.
126. Baba, M.; Takashima, K.; Miyake, H.; Kanzaki, N.; Teshima, K.; Wang, X.; Shiraishi, M.; Iizawa, Y. TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans. Antimicrob. Agents Chemother. 2005, 49, 4584-4591.
127. Dorr, P.; Westby, M.; Dobbs, S.; Griffin, P.; Irvine, B.; Macartney, M.; Mori, J.; Rickett, G.; Smith-Burchnell, C.; Napier, C.; et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother. 2005, 49, 4721-4732.
128. Takashima, K.; Miyake, H.; Kanzaki, N.; Tagawa, Y.; Wang, X.; Sugihara, Y.; Iizawa, Y.; Baba, M. Highly potent inhibition of human immunodeficiency virus type 1 replication by TAK-220, an orally bioavailable small-molecule CCR5 antagonist. Antimicrob. Agents Chemother. 2005, 49, 3474-3482.
129. Watson, C.; Jenkinson, S.; Kazmierski, W.; Kenakin, T. The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor. Mol. Pharmacol. 2005, 67, 1268-1282.
130. Seibert, C.; Ying, W.; Gavrilov, S.; Tsamis, F.; Kuhmann, S.E.; Palani, A.; Tagat, J.R.; Clader, J.W.; McCombie, S.W.; Baroudy, B.M.; et al. Interaction of small molecule inhibitors of HIV-1 entry with CCR5. Virology 2006, 349, 41-54.
131. Maeda, K.; Das, D.; Yin, P.D.; Tsuchiya, K.; Ogata-Aoki, H.; Nakata, H.; Norman, R.B.; Hackney, L.A.; Takaoka, Y.; Mitsuya, H. Involvement of the second extracellular loop and transmembrane residues of CCR5 in inhibitor binding and HIV-1 fusion: Insights into the mechanism of allosteric inhibition. J. Mol. Biol. 2008, 381, 956-974.
132. Muniz-Medina, V.M.; Jones, S.; Maglich, J.M.; Galardi, C.; Hollingsworth, R.E.; Kazmierski, W.M.; Ferris, R.G.; Edelstein, M.P.; Chiswell, K.E.; Kenakin, T.P. The relative activity of "function sparing" HIV-1 entry inhibitors on viral entry and CCR5 internalization: Is allosteric functional selectivity a valuable therapeutic property? Mol. Pharmacol. 2009, 75, 490-501.
133. Tilton, J.C.; Wilen, C.B.; Didigu, C.A.; Sinha, R.; Harrison, J.E.; Agrawal-Gamse, C.; Henning, E.A.; Bushman, F.D.; Martin, J.N.; Deeks, S.G.; et al. A maraviroc-resistant HIV-1 with narrow cross-resistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5. J. Virol. 2010, 84, 10863-10876.
134. Garcia-Perez, J.; Rueda, P.; Staropoli, I.; Kellenberger, E.; Alcami, J.; Arenzana-Seisdedos, F.; Lagane, B. New insights into the mechanisms whereby low molecular weight CCR5 ligands inhibit HIV-1 infection. J. Biol. Chem. 2011, 286, 4978-4990.
135. Maeda, K.; Das, D.; Ogata-Aoki, H.; Nakata, H.; Miyakawa, T.; Tojo, Y.; Norman, R.; Takaoka, Y.; Ding, J.; Arnold, G.F.; et al. Structural and molecular interactions of CCR5 inhibitors with CCR5. J. Biol. Chem. 2006, 281, 12688-12698.
136. Kondru, R.; Zhang, J.; Ji, C.; Mirzadegan, T.; Rotstein, D.; Sankuratri, S.; Dioszegi, M. Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists. Mol. Pharmacol. 2008, 73, 789-800.
137. Gilliam, B.L.; Riedel, D.J.; Redfield, R.R. Clinical use of CCR5 inhibitors in HIV and beyond. J. Trans. l Med. 2011, 9, S9.
138. Kanbara, K.; Sato, S.; Tanuma, J.; Tamamura, H.; Gotoh, K.; Yoshimori, M.; Kanamoto, T.; Kitano, M.; Fujii, N.; Nakashima, H. Biological and genetic characterization of a human immunodeficiency virus strain resistant to CXCR4 antagonist T134. AIDS Res. Hum. Retrovir. 2001, 17, 615-622.
139. Schols, D.; Este, J.A.; Cabrera, C.; de Clercq, E. T-cell-line-tropic human immunodeficiency virus type 1 that is made resistant to stromal cell-derived factor 1alpha contains mutations in the envelope gp120 but does not show a switch in coreceptor use. J. Virol. 1998, 72, 4032-4037.
140. De Vreese, K.; Kofler-Mongold, V.; Leutgeb, C.; Weber, V.; Vermeire, K.; Schacht, S.; Anne, J.; de Clercq, E.; Datema, R.; Werner, G. The molecular target of bicyclams, potent inhibitors of human immunodeficiency virus replication. J. Virol. 1996, 70, 689-696.
141. Este, J.A.; de Vreese, K.; Witvrouw, M.; Schmit, J.C.; Vandamme, A.M.; Anne, J.; Desmyter, J.; Henson, G.W.; Bridger, G.; de Clercq, E. Antiviral activity of the bicyclam derivative JM3100 against drug-resistant strains of human immunodeficiency virus type 1. Antivir. Res. 1996, 29, 297-307.
142. Este, J.A.; Schols, D.; de Vreese, K.; van Laethem, K.; Vandamme, A.M.; Desmyter, J.; de Clercq, E. Development of resistance of human immunodeficiency virus type 1 to dextran sulfate associated with the emergence of specific mutations in the envelope gp120 glycoprotein. Mol. Pharmacol. 1997, 52, 98-104.
143. Moulard, M.; Lortat-Jacob, H.; Mondor, I.; Roca, G.; Wyatt, R.; Sodroski, J.; Zhao, L.; Olson, W.; Kwong, P.D.; Sattentau, Q.J. Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120. J. Virol. 2000, 74, 1948-1960.
144. Este, J.A.; Cabrera, C.; Blanco, J.; Gutierrez, A.; Bridger, G.; Henson, G.; Clotet, B.; Schols, D.; de Clercq, E. Shift of clinical human immunodeficiency virus type 1 isolates from X4 to R5 and prevention of emergence of the syncytium-inducing phenotype by blockade of CXCR4. J. Virol. 1999, 73, 5577-5585.
145. Waters, L.; Mandalia, S.; Randell, P.; Wildfire, A.; Gazzard, B.; Moyle, G. The impact of HIV tropism on decreases in CD4 cell count, clinical progression, and subsequent response to a first antiretroviral therapy regimen. Clin. Infect. Dis. 2008, 46, 1617-1623.
146. Maeda, Y.; Foda, M.; Matsushita, S.; Harada, S. Involvement of both the V2 and V3 regions of the CCR5-tropic human immunodeficiency virus type 1 envelope in reduced sensitivity to macrophage inflammatory protein 1alpha. J. Virol. 2000, 74, 1787-1793.
147. Aarons, E.J.; Beddows, S.; Willingham, T.; Wu, L.; Koup, R.A. Adaptation to blockade of human immunodeficiency virus type 1 entry imposed by the anti-CCR5 monoclonal antibody 2D7. Virology 2001, 287, 382-390.
148. Mosier, D.E.; Picchio, G.R.; Gulizia, R.J.; Sabbe, R.; Poignard, P.; Picard, L.; Offord, R.E.; Thompson, D.A.; Wilken, J. Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants. J. Virol. 1999, 73, 3544-3550.
149. Trkola, A.; Kuhmann, S.E.; Strizki, J.M.; Maxwell, E.; Ketas, T.; Morgan, T.; Pugach, P.; Xu, S.; Wojcik, L.; Tagat, J.; et al. HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc. Natl. Acad. Sci. U. S. A. 2002, 99, 395-400.
150. Marozsan, A.J.; Kuhmann, S.E.; Morgan, T.; Herrera, C.; Rivera-Troche, E.; Xu, S.; Baroudy, B.M.; Strizki, J.; Moore, J.P. Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D). Virology 2005, 338, 182-199.
151. Westby, M.; Smith-Burchnell, C.; Mori, J.; Lewis, M.; Mosley, M.; Stockdale, M.; Dorr, P.; Ciaramella, G.; Perros, M. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J. Virol. 2007, 81, 2359-2371.
152. Strizki, J.M.; Tremblay, C.; Xu, S.; Wojcik, L.; Wagner, N.; Gonsiorek, W.; Hipkin, R.W.; Chou, C.C.; Pugliese-Sivo, C.; Xiao, Y.; et al. Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 2005, 49, 4911-4919.
153. Ogert, R.A.; Wojcik, L.; Buontempo, C.; Ba, L.; Buontempo, P.; Ralston, R.; Strizki, J.; Howe, J.A. Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120. Virology 2008, 373, 387-399.
154. Baba, M.; Miyake, H.; Wang, X.; Okamoto, M.; Takashima, K. Isolation and characterization of human immunodeficiency virus type 1 resistant to the small-molecule CCR5 antagonist TAK-652. Antimicrob. Agents Chemother. 2007, 51, 707-715.
155. Kitrinos, K.M.; Amrine-Madsen, H.; Irlbeck, D.M.; Word, J.M.; Demarest, J.F. Virologic failure in therapy-naive subjects on aplaviroc plus lopinavir-ritonavir: Detection of aplaviroc resistance requires clonal analysis of envelope. Antimicrob. Agents Chemother. 2009, 53, 1124-1131.
156. Westby, M.; Lewis, M.; Whitcomb, J.; Youle, M.; Pozniak, A.L.; James, I.T.; Jenkins, T.M.; Perros, M.; van der Ryst, E. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J. Virol. 2006, 80, 4909-4920.
157. Lalezari, J.; Thompson, M.; Kumar, P.; Piliero, P.; Davey, R.; Patterson, K.; Shachoy-Clark, A.; Adkison, K.; Demarest, J.; Lou, Y.; et al. Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults. AIDS 2005, 19, 1443-1448.
158. Fatkenheuer, G.; Pozniak, A.L.; Johnson, M.A.; Plettenberg, A.; Staszewski, S.; Hoepelman, A.I.; Saag, M.S.; Goebel, F.D.; Rockstroh, J.K.; Dezube, B.J.; et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat. Med. 2005, 11, 1170-1172.
159. Gulick, R.M.; Su, Z.; Flexner, C.; Hughes, M.D.; Skolnik, P.R.; Wilkin, T.J.; Gross, R.; Krambrink, A.; Coakley, E.; Greaves, W.L.; et al. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211. J. Infect. Dis. 2007, 196, 304-312.
160. Schurmann, D.; Fatkenheuer, G.; Reynes, J.; Michelet, C.; Raffi, F.; van Lier, J.; Caceres, M.; Keung, A.; Sansone-Parsons, A.; Dunkle, L.M.; et al. Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults. AIDS 2007, 21, 1293-1299.
161. Fatkenheuer, G.; Nelson, M.; Lazzarin, A.; Konourina, I.; Hoepelman, A.I.; Lampiris, H.; Hirschel, B.; Tebas, P.; Raffi, F.; Trottier, B.; et al. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. New Engl. J. Med. 2008, 359, 1442-1455.
162. Landovitz, R.J.; Angel, J.B.; Hoffmann, C.; Horst, H.; Opravil, M.; Long, J.; Greaves, W.; Fatkenheuer, G. Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection. J. Infect. Dis. 2008, 198, 1113-1122.
163. Tsibris, A.M.; Sagar, M.; Gulick, R.M.; Su, Z.; Hughes, M.; Greaves, W.; Subramanian, M.; Flexner, C.; Giguel, F.; Leopold, K.E.; et al. In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject. J. Virol. 2008, 82, 8210-8214.
164. Yeni, P.; Lamarca, A.; Berger, D.; Cimoch, P.; Lazzarin, A.; Salvato, P.; Smaill, F.M.; Teofilo, E.; Madison, S.J.; Nichols, W.G.; et al. Antiviral activity and safety of aplaviroc, a CCR5 antagonist, in combination with lopinavir/ritonavir in HIV-infected, therapy-naive patients: Results of the EPIC study (CCR100136). HIV Med. 2009, 10, 116-124.
165. Gulick, R.M.; Lalezari, J.; Goodrich, J.; Clumeck, N.; DeJesus, E.; Horban, A.; Nadler, J.; Clotet, B.; Karlsson, A.; Wohlfeiler, M.; et al. Maraviroc for previously treated patients with R5 HIV-1 infection. New Engl. J. Med. 2008, 359, 1429-1441.
166. Cooper, D.A.; Heera, J.; Goodrich, J.; Tawadrous, M.; Saag, M.; Dejesus, E.; Clumeck, N.; Walmsley, S.; Ting, N.; Coakley, E.; et al. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J. Infect. Dis. 2010, 201, 803-813.
167. Baatz, F.; Struck, D.; Lemaire, M.; de Landtsheer, S.; Servais, J.Y.; Arendt, V.; Schmit, J.C.; Perez Bercoff, D. Rescue of HIV-1 long-time archived X4 strains to escape maraviroc. Antivir. Res. 2011, 92, 488-492.
168. Cilliers, T.; Nhlapo, J.; Coetzer, M.; Orlovic, D.; Ketas, T.; Olson, W.C.; Moore, J.P.; Trkola, A.; Morris, L. The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C. J. Virol. 2003, 77, 4449-4456.
169. Coetzer, M.; Nedellec, R.; Cilliers, T.; Meyers, T.; Morris, L.; Mosier, D.E. Extreme genetic divergence is required for coreceptor switching in HIV-1 subtype C. J. Acquir. Immune Defic. Syndr. 2011, 56, 9-15.
170. Kuhmann, S.E.; Pugach, P.; Kunstman, K.J.; Taylor, J.; Stanfield, R.L.; Snyder, A.; Strizki, J.M.; Riley, J.; Baroudy, B.M.; Wilson, I.A.; et al. Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor. J. Virol. 2004, 78, 2790-2807.
171. Pugach, P.; Marozsan, A.J.; Ketas, T.J.; Landes, E.L.; Moore, J.P.; Kuhmann, S.E. HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry. Virology 2007, 361, 212-228.
172. Anastassopoulou, C.G.; Ketas, T.J.; Klasse, P.J.; Moore, J.P. Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41. Proc. Natl. Acad. Sci. U. S. A. 2009, 106, 5318-5323.
173. Berro, R.; Sanders, R.W.; Lu, M.; Klasse, P.J.; Moore, J.P. Two HIV-1 variants resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entry. PLoS Pathog. 2009, 5, e1000548.
174. Nolan, K.M.; Del Prete, G.Q.; Jordan, A.P.; Haggarty, B.; Romano, J.; Leslie, G.J.; Hoxie, J.A. Characterization of a human immunodeficiency virus type 1 V3 deletion mutation that confers resistance to CCR5 inhibitors and the ability to use aplaviroc-bound receptor. J. Virol. 2009, 83, 3798-3809.
175. Berro, R.; Klasse, P.J.; Jakobsen, M.R.; Gorry, P.R.; Moore, J.P.; Sanders, R.W. V3 determinants of HIV-1 escape from the CCR5 inhibitors Maraviroc and Vicriviroc. Virology 2012, 427, 158-165.
176. Ogert, R.A.; Ba, L.; Hou, Y.; Buontempo, C.; Qiu, P.; Duca, J.; Murgolo, N.; Buontempo, P.; Ralston, R.; Howe, J.A. Structure-function analysis of human immunodeficiency virus type 1 gp120 amino acid mutations associated with resistance to the CCR5 coreceptor antagonist vicriviroc. J. Virol. 2009, 83, 12151-12163.
177. Yuan, Y.; Maeda, Y.; Terasawa, H.; Monde, K.; Harada, S.; Yusa, K. A combination of polymorphic mutations in V3 loop of HIV-1 gp120 can confer noncompetitive resistance to maraviroc. Virology 2011, 413, 293-299.
178. Laakso, M.M.; Lee, F.H.; Haggarty, B.; Agrawal, C.; Nolan, K.M.; Biscone, M.; Romano, J.; Jordan, A.P.; Leslie, G.J.; Meissner, E.G.; et al. V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies. PLoS Pathog. 2007, 3, e117.
179. Yusa, K.; Maeda, Y.; Fujioka, A.; Monde, K.; Harada, S. Isolation of TAK-779-resistant HIV-1 from an R5 HIV-1 GP120 V3 loop library. J. Biol. Chem. 2005, 280, 30083-30090.
180. McNicholas, P.M.; Mann, P.A.; Wojcik, L.; Phd, P.Q.; Lee, E.; McCarthy, M.; Shen, J.; Black, T.A.; Strizki, J.M. Mapping and characterization of vicriviroc resistance mutations from HIV-1 isolated from treatment-experienced subjects enrolled in a phase II study (VICTOR-E1). J. Acquir. Immune Defic. Syndr. 2011, 56, 222-229.
181. Ogert, R.A.; Hou, Y.; Ba, L.; Wojcik, L.; Qiu, P.; Murgolo, N.; Duca, J.; Dunkle, L.M.; Ralston, R.; Howe, J.A. Clinical resistance to vicriviroc through adaptive V3 loop mutations in HIV-1 subtype D gp120 that alter interactions with the N-terminus and ECL2 of CCR5. Virology 2010, 400, 145-155.
182. Pfaff, J.M.; Wilen, C.B.; Harrison, J.E.; Demarest, J.F.; Lee, B.; Doms, R.W.; Tilton, J.C. HIV-1 resistance to CCR5 antagonists associated with highly efficient use of CCR5 and altered tropism on primary CD4+ T cells. J. Virol. 2010, 84, 6505-6514.
183. McNicholas, P.; Wei, Y.; Whitcomb, J.; Greaves, W.; Black, T.A.; Tremblay, C.L.; Strizki, J.M. Characterization of emergent HIV resistance in treatment-naive subjects enrolled in a vicriviroc phase 2 trial. J. Infect. Dis. 2010, 201, 1470-1480.
184. Henrich, T.J.; Tsibris, A.M.; Lewine, N.R.; Konstantinidis, I.; Leopold, K.E.; Sagar, M.; Kuritzkes, D.R. Evolution of CCR5 antagonist resistance in an HIV-1 subtype C clinical isolate. J. Acquir. Immune Defic. Syndr. 2010, 55, 420-427.
185. Anastassopoulou, C.G.; Ketas, T.J.; Depetris, R.S.; Thomas, A.M.; Klasse, P.J.; Moore, J.P. Resistance of a human immunodeficiency virus type 1 isolate to a small molecule CCR5 inhibitor can involve sequence changes in both gp120 and gp41. Virology 2011, 413, 47-59.
186. Moore, J.P.; Kuritzkes, D.R. A piece de resistance: How HIV-1 escapes small molecule CCR5 inhibitors. Curr. Opin. HIV AIDS 2009, 4, 118-124.
187. Lobritz, M.A.; Ratcliff, A.N.; Arts, E.J. HIV-1 Entry, Inhibitors, and Resistance. Viruses 2010, 2, 1069-1105.
188. Tilton, J.C.; Amrine-Madsen, H.; Miamidian, J.L.; Kitrinos, K.M.; Pfaff, J.; Demarest, J.F.; Ray, N.; Jeffrey, J.L.; Labranche, C.C.; Doms, R.W. HIV type 1 from a patient with baseline resistance to CCR5 antagonists uses drug-bound receptor for entry. AIDS Res. Hum. Retrovir. 2010, 26, 13-24.
189. Pugach, P.; Ray, N.; Klasse, P.J.; Ketas, T.J.; Michael, E.; Doms, R.W.; Lee, B.; Moore, J.P. Inefficient entry of vicriviroc-resistant HIV-1 via the inhibitor-CCR5 complex at low cell surface CCR5 densities. Virology 2009, 387, 296-302.
190. Heredia, A.; Latinovic, O.; Gallo, R.C.; Melikyan, G.; Reitz, M.; Le, N.; Redfield, R.R. Reduction of CCR5 with low-dose rapamycin enhances the antiviral activity of vicriviroc against both sensitive and drug-resistant HIV-1. Proc. Natl. Acad. Sci. U. S. A. 2008, 105, 20476-20481.
191. Baribaud, F.; Edwards, T.G.; Sharron, M.; Brelot, A.; Heveker, N.; Price, K.; Mortari, F.; Alizon, M.; Tsang, M.; Doms, R.W. Antigenically distinct conformations of CXCR4. J. Virol. 2001, 75, 8957-8967.
192. Berro, R.; Klasse, P.J.; Lascano, D.; Flegler, A.; Nagashima, K.A.; Sanders, R.W.; Sakmar, T.P.; Hope, T.J.; Moore, J.P. Multiple CCR5 conformations on the cell surface are used differentially by human immunodeficiency viruses resistant or sensitive to CCR5 inhibitors. J. Virol. 2011, 85, 8227-8240.
193. Platt, E.J.; Durnin, J.P.; Shinde, U.; Kabat, D. An allosteric rheostat in HIV-1 gp120 reduces CCR5 stoichiometry required for membrane fusion and overcomes diverse entry limitations. J. Mol. Biol. 2007, 374, 64-79.
194. Reeves, J.D.; Gallo, S.A.; Ahmad, N.; Miamidian, J.L.; Harvey, P.E.; Sharron, M.; Pohlmann, S.; Sfakianos, J.N.; Derdeyn, C.A.; Blumenthal, R.; et al. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc. Natl. Acad. Sci. U. S. A. 2002, 99, 16249-16254.
195. Putcharoen, O.; Lee, S.H.; Henrich, T.J.; Hu, Z.; Vanichanan, J.; Coakley, E.; Greaves, W.; Gulick, R.M.; Kuritzkes, D.R.; Tsibris, A.M. HIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that are corrected in the presence of drug. J. Virol. 2012, 86, 1119-1128.
196. Anastassopoulou, C.G.; Ketas, T.J.; Sanders, R.W.; Klasse, P.J.; Moore, J.P. Effects of sequence changes in the HIV-1 gp41 fusion peptide on CCR5 inhibitor resistance. Virology 2012, 428, 86-97.
197. Anastassopoulou, C.G.; Marozsan, A.J.; Matet, A.; Snyder, A.D.; Arts, E.J.; Kuhmann, S.E.; Moore, J.P. Escape of HIV-1 from a small molecule CCR5 inhibitor is not associated with a fitness loss. PLoS Pathog. 2007, 3, e79.
198. Tsibris, A.M.; Korber, B.; Arnaout, R.; Russ, C.; Lo, C.C.; Leitner, T.; Gaschen, B.; Theiler, J.; Paredes, R.; Su, Z.; et al. Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo. PLoS One 2009, 4, e5683.
199. Tsibris, A.M.; Hu, Z.; Paredes, R.; Leopold, K.E.; Putcharoen, O.; Schure, A.L.; Mazur, N.; Coakley, E.; Su, Z.; Gulick, R.M.; et al. Vicriviroc resistance decay and relative replicative fitness in HIV-1 clinical isolates under sequential drug selection pressures. J. Virol. 2012, 86, 6416-6426.
200. White, J.M.; Delos, S.E.; Brecher, M.; Schornberg, K. Structures and mechanisms of viral membrane fusion proteins: Multiple variations on a common theme. Crit. Rev. Biochem. Mol. Biol. 2008, 43, 189-219.
201. Melikyan, G.B.; Markosyan, R.M.; Hemmati, H.; Delmedico, M.K.; Lambert, D.M.; Cohen, F.S. Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion. J. Cell Biol. 2000, 151, 413-423.
202. Herskowitz, I. Functional inactivation of genes by dominant negative mutations. Nature 1987, 329, 219-222.
203. Amaya, E.; Musci, T.J.; Kirschner, M.W. Expression of a dominant negative mutant of the FGF receptor disrupts mesoderm formation in Xenopus embryos. Cell 1991, 66, 257-270.
204. Matthews, T.J.; Wild, C.; Chen, C.H.; Bolognesi, D.P.; Greenberg, M.L. Structural rearrangements in the transmembrane glycoprotein after receptor binding. Immunol. Rev. 1994, 140, 93-104.
205. Highlights of prescribing information. Available online: http://www.accessdata.fda.gov/ drugsatfda_docs/label/2012/021481s025lbl.pdf (accessed on 6 November 2012).
206. Lalezari, J.P.; Henry, K.; O'Hearn, M.; Montaner, J.S.; Piliero, P.J.; Trottier, B.; Walmsley, S.; Cohen, C.; Kuritzkes, D.R.; Eron, J.J., Jr.; et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. New Engl. J. Med. 2003, 348, 2175-2185.
207. Kilby, J.M.; Hopkins, S.; Venetta, T.M.; DiMassimo, B.; Cloud, G.A.; Lee, J.Y.; Alldredge, L.; Hunter, E.; Lambert, D.; Bolognesi, D.; et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat. Med. 1998, 4, 1302-1307.
208. Kilby, J.M.; Eron, J.J. Novel therapies based on mechanisms of HIV-1 cell entry. New Engl. J. Med. 2003, 348, 2228-2238.
209. Wild, C.T.; Shugars, D.C.; Greenwell, T.K.; McDanal, C.B.; Matthews, T.J. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc. Natl. Acad. Sci. U. S. A. 1994, 91, 9770-9774.
210. Wild, C.; Oas, T.; McDanal, C.; Bolognesi, D.; Matthews, T. A synthetic peptide inhibitor of human immunodeficiency virus replication: Correlation between solution structure and viral inhibition. Proc. Natl. Acad. Sci. U. S. A. 1992, 89, 10537-10541.
211. Jiang, S.; Lin, K.; Strick, N.; Neurath, A.R. HIV-1 inhibition by a peptide. Nature 1993, 365, 113.
212. Wild, C.; Greenwell, T.; Shugars, D.; Rimsky-Clarke, L.; Matthews, T. The inhibitory activity of an HIV type 1 peptide correlates with its ability to interact with a leucine zipper structure. AIDS Res. Hum. Retrovir. 1995, 11, 323-325.
213. Chen, C.H.; Matthews, T.J.; McDanal, C.B.; Bolognesi, D.P.; Greenberg, M.L. A molecular clasp in the human immunodeficiency virus (HIV) type 1 TM protein determines the anti-HIV activity of gp41 derivatives: Implication for viral fusion. J. Virol. 1995, 69, 3771-3777.
214. Tan, K.; Liu, J.; Wang, J.; Shen, S.; Lu, M. Atomic structure of a thermostable subdomain of HIV-1 gp41. Proc. Natl. Acad. Sci. U. S. A. 1997, 94, 12303-12308.
215. Weissenhorn, W.; Dessen, A.; Harrison, S.C.; Skehel, J.J.; Wiley, D.C. Atomic structure of the ectodomain from HIV-1 gp41. Nature 1997, 387, 426-430.
216. Lu, M.; Blacklow, S.C.; Kim, P.S. A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat. Struct. Biol. 1995, 2, 1075-1082.
217. Chan, D.C.; Kim, P.S. HIV entry and its inhibition. Cell 1998, 93, 681-684.
218. Chan, D.C.; Fass, D.; Berger, J.M.; Kim, P.S. Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997, 89, 263-273.
219. Liu, S.; Jing, W.; Cheung, B.; Lu, H.; Sun, J.; Yan, X.; Niu, J.; Farmar, J.; Wu, S.; Jiang, S. HIV gp41 C-terminal heptad repeat contains multifunctional domains. Relation to mechanisms of action of anti-HIV peptides. J. Biol. Chem. 2007, 282, 9612-9620.
220. Kliger, Y.; Gallo, S.A.; Peisajovich, S.G.; Munoz-Barroso, I.; Avkin, S.; Blumenthal, R.; Shai, Y. Mode of action of an antiviral peptide from HIV-1. Inhibition at a post-lipid mixing stage. J. Biol. Chem. 2001, 276, 1391-1397.
221. Yuan, W.; Craig, S.; Si, Z.; Farzan, M.; Sodroski, J. CD4-induced T-20 binding to human immunodeficiency virus type 1 gp120 blocks interaction with the CXCR4 coreceptor. J. Virol. 2004, 78, 5448-5457.
222. Alam, S.M.; Paleos, C.A.; Liao, H.X.; Scearce, R.; Robinson, J.; Haynes, B.F. An inducible HIV type 1 gp41 HR-2 peptide-binding site on HIV type 1 envelope gp120. AIDS Res. Hum. Retrovir. 2004, 20, 836-845.
223. He, Y.; Vassell, R.; Zaitseva, M.; Nguyen, N.; Yang, Z.; Weng, Y.; Weiss, C.D. Peptides trap the human immunodeficiency virus type 1 envelope glycoprotein fusion intermediate at two sites. J. Virol. 2003, 77, 1666-1671.
224. Furuta, R.A.; Wild, C.T.; Weng, Y.; Weiss, C.D. Capture of an early fusion-active conformation of HIV-1 gp41. Nat. Struct. Biol. 1998, 5, 276-279.
225. Koshiba, T.; Chan, D.C. The prefusogenic intermediate of HIV-1 gp41 contains exposed C-peptide regions. J. Biol. Chem. 2003, 278, 7573-7579.
226. Kilgore, N.R.; Salzwedel, K.; Reddick, M.; Allaway, G.P.; Wild, C.T. Direct evidence that C-peptide inhibitors of human immunodeficiency virus type 1 entry bind to the gp41 N-helical domain in receptor-activated viral envelope. J. Virol. 2003, 77, 7669-7672.
227. Rimsky, L.T.; Shugars, D.C.; Matthews, T.J. Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J. Virol. 1998, 72, 986-993.
228. Wei, X.; Decker, J.M.; Liu, H.; Zhang, Z.; Arani, R.B.; Kilby, J.M.; Saag, M.S.; Wu, X.; Shaw, G.M.; Kappes, J.C. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 2002, 46, 1896-1905.
229. Sista, P.R.; Melby, T.; Davison, D.; Jin, L.; Mosier, S.; Mink, M.; Nelson, E.L.; DeMasi, R.; Cammack, N.; Salgo, M.P.; et al. Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates. AIDS 2004, 18, 1787-1794.
230. Poveda, E.; Rodes, B.; Toro, C.; Martin-Carbonero, L.; Gonzalez-Lahoz, J.; Soriano, V. Evolution of the gp41 env region in HIV-infected patients receiving T-20, a fusion inhibitor. AIDS 2002, 16, 1959-1961.
231. Baldwin, C.E.; Sanders, R.W.; Deng, Y.; Jurriaans, S.; Lange, J.M.; Lu, M.; Berkhout, B. Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor. J. Virol. 2004, 78, 12428-12437.
232. Nameki, D.; Kodama, E.; Ikeuchi, M.; Mabuchi, N.; Otaka, A.; Tamamura, H.; Ohno, M.; Fujii, N.; Matsuoka, M. Mutations conferring resistance to human immunodeficiency virus type 1 fusion inhibitors are restricted by gp41 and Rev-responsive element functions. J. Virol. 2005, 79, 764-770.
233. Poveda, E.; Rodes, B.; Lebel-Binay, S.; Faudon, J.L.; Jimenez, V.; Soriano, V. Dynamics of enfuvirtide resistance in HIV-infected patients during and after long-term enfuvirtide salvage therapy. J. Clin. Virol. 2005, 34, 295-301.
234. Perez-Alvarez, L.; Carmona, R.; Ocampo, A.; Asorey, A.; Miralles, C.; Perez de Castro, S.; Pinilla, M.; Contreras, G.; Taboada, J.A.; Najera, R. Long-term monitoring of genotypic and phenotypic resistance to T20 in treated patients infected with HIV-1. J. Med. Virol. 2006, 78, 141-147.
235. Xu, L.; Pozniak, A.; Wildfire, A.; Stanfield-Oakley, S.A.; Mosier, S.M.; Ratcliffe, D.; Workman, J.; Joall, A.; Myers, R.; Smit, E.; et al. Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41. Antimicrob. Agents Chemother. 2005, 49, 1113-1119.
236. Cilliers, T.; Moore, P.; Coetzer, M.; Morris, L. in vitro generation of HIV type 1 subtype C isolates resistant to enfuvirtide. AIDS Res. Hum. Retrovir. 2005, 21, 776-783.
237. Cabrera, C.; Marfil, S.; Garcia, E.; Martinez-Picado, J.; Bonjoch, A.; Bofill, M.; Moreno, S.; Ribera, E.; Domingo, P.; Clotet, B.; et al. Genetic evolution of gp41 reveals a highly exclusive relationship between codons 36, 38 and 43 in gp41 under long-term enfuvirtide-containing salvage regimen. AIDS 2006, 20, 2075-2080.
238. Menzo, S.; Castagna, A.; Monachetti, A.; Hasson, H.; Danise, A.; Carini, E.; Bagnarelli, P.; Lazzarin, A.; Clementi, M. Genotype and phenotype patterns of human immunodeficiency virus type 1 resistance to enfuvirtide during long-term treatment. Antimicrob. Agents Chemother. 2004, 48, 3253-3259.
239. Ray, N.; Harrison, J.E.; Blackburn, L.A.; Martin, J.N.; Deeks, S.G.; Doms, R.W. Clinical resistance to enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitors. J. Virol. 2007, 81, 3240-3250.
240. Lu, J.; Deeks, S.G.; Hoh, R.; Beatty, G.; Kuritzkes, B.A.; Martin, J.N.; Kuritzkes, D.R. Rapid emergence of enfuvirtide resistance in HIV-1-infected patients: Results of a clonal analysis. J. Acquir. Immune Defic. Syndr. 2006, 43, 60-64.
241. Mink, M.; Mosier, S.M.; Janumpalli, S.; Davison, D.; Jin, L.; Melby, T.; Sista, P.; Erickson, J.; Lambert, D.; Stanfield-Oakley, S.A.; et al. Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro. J. Virol. 2005, 79, 12447-12454.
242. Trivedi, V.D.; Cheng, S.F.; Wu, C.W.; Karthikeyan, R.; Chen, C.J.; Chang, D.K. The LLSGIV stretch of the N-terminal region of HIV-1 gp41 is critical for binding to a model peptide, T20. Protein Eng. 2003, 16, 311-317.
243. Hanna, S.L.; Yang, C.; Owen, S.M.; Lal, R.B. Variability of critical epitopes within HIV-1 heptad repeat domains for selected entry inhibitors in HIV-infected populations worldwide [corrected]. AIDS 2002, 16, 1603-1608.
244. Labrosse, B.; Labernardiere, J.L.; Dam, E.; Trouplin, V.; Skrabal, K.; Clavel, F.; Mammano, F. Baseline susceptibility of primary human immunodeficiency virus type 1 to entry inhibitors. J. Virol. 2003, 77, 1610-1613.
245. Xu, L.; Hue, S.; Taylor, S.; Ratcliffe, D.; Workman, J.A.; Jackson, S.; Cane, P.A.; Pillay, D. Minimal variation in T-20 binding domain of different HIV-1 subtypes from antiretroviral-naive and-experienced patients. AIDS 2002, 16, 1684-1686.
246. Zollner, B.; Feucht, H.H.; Schroter, M.; Schafer, P.; Plettenberg, A.; Stoehr, A.; Laufs, R. Primary genotypic resistance of HIV-1 to the fusion inhibitor T-20 in long-term infected patients. AIDS 2001, 15, 935-936.
247. Roman, F.; Gonzalez, D.; Lambert, C.; Deroo, S.; Fischer, A.; Baurith, T.; Staub, T.; Boulme, R.; Arendt, V.; Schneider, F.; et al. Uncommon mutations at residue positions critical for enfuvirtide (T-20) resistance in enfuvirtide-naive patients infected with subtype B and non-B HIV-1 strains. J. Acquir. Immune Defic. Syndr. 2003, 33, 134-139.
248. Villahermosa, M.L.; Perez-Alvarez, L.; Carmona, R.; Cuevas, M.T.; Thomson, M.M.; Medrano, L.; Vazquez de Parga, E.; Delgado, E.; Pedreira, J.D.; Najera, R. Primary resistance mutations to fusion inhibitors and polymorphisms in gp41 sequences of HIV-1 non-B subtypes and recombinants. AIDS 2003, 17, 1083-1086.
249. Loutfy, M.R.; Raboud, J.M.; Montaner, J.S.; Antoniou, T.; Wynhoven, B.; Smaill, F.; Rouleau, D.; Gill, J.; Schlech, W.; Brumme, Z.L.; et al. Assay of HIV gp41 amino acid sequence to identify baseline variation and mutation development in patients with virologic failure on enfuvirtide. Antivir. Res. 2007, 75, 58-63.
250. Caffrey, M. Model for the structure of the HIV gp41 ectodomain: Insight into the intermolecular interactions of the gp41 loop. Biochim. Biophys. Acta 2001, 1536, 116-122.
251. Caffrey, M.; Cai, M.; Kaufman, J.; Stahl, S.J.; Wingfield, P.T.; Covell, D.G.; Gronenborn, A.M.; Clore, G.M. Three-dimensional solution structure of the 44 kDa ectodomain of SIV gp41. EMBO J. 1998, 17, 4572-4584.
252. Melby, T.; Sista, P.; DeMasi, R.; Kirkland, T.; Roberts, N.; Salgo, M.; Heilek-Snyder, G.; Cammack, N.; Matthews, T.J.; Greenberg, M.L. Characterization of envelope glycoprotein gp41 genotype and phenotypic susceptibility to enfuvirtide at baseline and on treatment in the phase III clinical trials TORO-1 and TORO-2. AIDS Res. Hum. Retrovir. 2006, 22, 375-385.
253. Tolstrup, M.; Selzer-Plon, J.; Laursen, A.L.; Bertelsen, L.; Gerstoft, J.; Duch, M.; Pedersen, F.S.; Ostergaard, L. Full fusion competence rescue of the enfuvirtide resistant HIV-1 gp41 genotype (43D) by a prevalent polymorphism (137K). AIDS 2007, 21, 519-521.
254. Ray, N.; Blackburn, L.A.; Doms, R.W. HR-2 mutations in human immunodeficiency virus type 1 gp41 restore fusion kinetics delayed by HR-1 mutations that cause clinical resistance to enfuvirtide. J. Virol. 2009, 83, 2989-2995.
255. Bai, X.; Wilson, K.L.; Seedorff, J.E.; Ahrens, D.; Green, J.; Davison, D.K.; Jin, L.; Stanfield-Oakley, S.A.; Mosier, S.M.; Melby, T.E.; et al. Impact of the enfuvirtide resistance mutation N43D and the associated baseline polymorphism E137K on peptide sensitivity and six-helix bundle structure. Biochemistry 2008, 47, 6662-6670.
256. Baatz, F.; Nijhuis, M.; Lemaire, M.; Riedijk, M.; Wensing, A.M.; Servais, J.Y.; van Ham, P.M.; Hoepelman, A.I.; Koopmans, P.P.; Sprenger, H.G.; et al. Impact of the HIV-1 env genetic context outside HR1-HR2 on resistance to the fusion inhibitor enfuvirtide and viral infectivity in clinical isolates. PLoS One 2011, 6, e21535.
257. Holguin, A.; Faudon, J.L.; Labernardiere, J.L.; Soriano, V. Susceptibility of HIV-1 non-B subtypes and recombinant variants to Enfuvirtide. J. Clin. Virol. 2007, 38, 176-180.
258. Labrosse, B.; Morand-Joubert, L.; Goubard, A.; Rochas, S.; Labernardiere, J.L.; Pacanowski, J.; Meynard, J.L.; Hance, A.J.; Clavel, F.; Mammano, F. Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients. J. Virol. 2006, 80, 8807-8819.
259. Goubard, A.; Clavel, F.; Mammano, F.; Labrosse, B. In vivo selection by enfuvirtide of HIV type-1 env quasispecies with optimal potential for phenotypic expression of HR1 mutations. Antivir. Ther. 2009, 14, 597-602.
260. Lu, J.; Sista, P.; Giguel, F.; Greenberg, M.; Kuritzkes, D.R. Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20). J. Virol. 2004, 78, 4628-4637.
261. Marconi, V.; Bonhoeffer, S.; Paredes, R.; Lu, J.; Hoh, R.; Martin, J.N.; Deeks, S.G.; Kuritzkes, D.R. Viral dynamics and in vivo fitness of HIV-1 in the presence and absence of enfuvirtide. J. Acquir. Immune Defic. Syndr. 2008, 48, 572-576.
262. Watabe, T.; Terakawa, Y.; Watanabe, K.; Ohno, H.; Nakano, H.; Nakatsu, T.; Kato, H.; Izumi, K.; Kodama, E.; Matsuoka, M.; et al. X-ray crystallographic study of an HIV-1 fusion inhibitor with the gp41 S138A substitution. J. Mol. Biol. 2009, 392, 657-665.
263. Baldwin, C.; Berkhout, B. Mechanistic studies of a T20-dependent human immunodeficiency virus type 1 variant. J. Virol. 2008, 82, 7735-7740.
264. Chan, D.C.; Chutkowski, C.T.; Kim, P.S. Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc. Natl. Acad. Sci. U. S. A. 1998, 95, 15613-15617.
265. Otaka, A.; Nakamura, M.; Nameki, D.; Kodama, E.; Uchiyama, S.; Nakamura, S.; Nakano, H.; Tamamura, H.; Kobayashi, Y.; Matsuoka, M.; et al. Remodeling of gp41-C34 peptide leads to highly effective inhibitors of the fusion of HIV-1 with target cells. Angew. Chem. 2002, 41, 2937-2940.
266. Derdeyn, C.A.; Decker, J.M.; Sfakianos, J.N.; Zhang, Z.; O'Brien, W.A.; Ratner, L.; Shaw, G.M.; Hunter, E. Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor. J. Virol. 2001, 75, 8605-8614.
267. He, Y.; Cheng, J.; Li, J.; Qi, Z.; Lu, H.; Dong, M.; Jiang, S.; Dai, Q. Identification of a critical motif for the human immunodeficiency virus type 1 (HIV-1) gp41 core structure: Implications for designing novel anti-HIV fusion inhibitors. J. Virol. 2008, 82, 6349-6358.
268. Greenberg, M.L.; Davison, D.; Jin, L.; Mosier, S.; Melby, T.; Sista, P.; Demasi, R.; Miralles, D.; Cammack, N.; Matthews, T.J. in vitro antiviral activity of T-1249, a second generation fusion inhibitor. Antivir. Ther. 2002, 7, S10.
269. Eron, J.J.; Gulick, R.M.; Bartlett, J.A.; Merigan, T.; Arduino, R.; Kilby, J.M.; Yangco, B.; Diers, A.; Drobnes, C.; DeMasi, R.; et al. Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV. J. Infect. Dis. 2004, 189, 1075-1083.
270. Chong, H.; Yao, X.; Sun, J.; Qiu, Z.; Zhang, M.; Waltersperger, S.; Wang, M.; Cui, S.; He, Y. The M-T Hook Structure Is Critical for Design of HIV-1 Fusion Inhibitors. J. Biol. Chem. 2012, 287, 34558-34568.
271. Chong, H.; Yao, X.; Qiu, Z.; Qin, B.; Han, R.; Waltersperger, S.; Wang, M.; Cui, S.; He, Y. Discovery of critical residues for viral entry and inhibition through structural Insight of HIV-1 fusion inhibitor CP621-652. J. Biol. Chem. 2012, 287, 20281-20289.
272. Melby, T.; Demasi, R.; Cammack, N.; Miralles, G.D.; Greenberg, M.L. Evolution of genotypic and phenotypic resistance during chronic treatment with the fusion inhibitor T-1249. AIDS Res. Hum. Retrovir. 2007, 23, 1366-1373.
273. Chinnadurai, R.; Rajan, D.; Munch, J.; Kirchhoff, F. Human immunodeficiency virus type 1 variants resistant to first-and second-version fusion inhibitors and cytopathic in ex vivo human lymphoid tissue. J. Virol. 2007, 81, 6563-6572.
274. Eggink, D.; Baldwin, C.E.; Deng, Y.; Langedijk, J.P.; Lu, M.; Sanders, R.W.; Berkhout, B. Selection of T1249-resistant human immunodeficiency virus type 1 variants. J. Virol. 2008, 82, 6678-6688.
275. Lalezari, J.P.; Bellos, N.C.; Sathasivam, K.; Richmond, G.J.; Cohen, C.J.; Myers, R.A., Jr.; Henry, D.H.; Raskino, C.; Melby, T.; Murchison, H.; et al. T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimen. J. Infect. Dis. 2005, 191, 1155-1163.
276. Armand-Ugon, M.; Gutierrez, A.; Clotet, B.; Este, J.A. HIV-1 resistance to the gp41-dependent fusion inhibitor C-34. Antivir. Res. 2003, 59, 137-142.
277. Eggink, D.; Langedijk, J.P.; Bonvin, A.M.; Deng, Y.; Lu, M.; Berkhout, B.; Sanders, R.W. Detailed mechanistic insights into HIV-1 sensitivity to three generations of fusion inhibitors. J. Biol. Chem. 2009, 284, 26941-26950.
278. Naito, T.; Izumi, K.; Kodama, E.; Sakagami, Y.; Kajiwara, K.; Nishikawa, H.; Watanabe, K.; Sarafianos, S.G.; Oishi, S.; Fujii, N.; et al. SC29EK, a peptide fusion inhibitor with enhanced alpha-helicity, inhibits replication of human immunodeficiency virus type 1 mutants resistant to enfuvirtide. Antimicrob. Agents Chemother. 2009, 53, 1013-1018.
279. Nishikawa, H.; Nakamura, S.; Kodama, E.; Ito, S.; Kajiwara, K.; Izumi, K.; Sakagami, Y.; Oishi, S.; Ohkubo, T.; Kobayashi, Y.; et al. Electrostatically constrained alpha-helical peptide inhibits replication of HIV-1 resistant to enfuvirtide. Int. J. Biochem. Cell Biol. 2009, 41, 891-899.
280. He, Y.; Cheng, J.; Lu, H.; Li, J.; Hu, J.; Qi, Z.; Liu, Z.; Jiang, S.; Dai, Q. Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strains. Proc. Natl. Acad. Sci. U. S. A. 2008, 105, 16332-16337.
281. He, Y.; Xiao, Y.; Song, H.; Liang, Q.; Ju, D.; Chen, X.; Lu, H.; Jing, W.; Jiang, S.; Zhang, L. Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor. J. Biol. Chem. 2008, 283, 11126-11134.
282. Yao, X.; Chong, H.; Zhang, C.; Qiu, Z.; Qin, B.; Han, R.; Waltersperger, S.; Wang, M.; He, Y.; Cui, S. Structural basis of potent and broad HIV-1 fusion inhibitor CP32M. J. Biol. Chem. 2012, 287, 26618-26629.
283. Yao, X.; Chong, H.; Zhang, C.; Waltersperger, S.; Wang, M.; Cui, S.; He, Y. Broad antiviral activity and crystal structure of HIV-1 fusion inhibitor sifuvirtide. J. Biol. Chem. 2012, 287, 6788-6796.
284. Yu, X.; Lu, L.; Cai, L.; Tong, P.; Tan, S.; Zou, P.; Meng, F.; Chen, Y.H.; Jiang, S. Mutations of Gln64 in the HIV-1 gp41 N-terminal heptad repeat render viruses resistant to peptide HIV fusion inhibitors targeting the gp41 pocket. J. Virol. 2012, 86, 589-593.
285. Liu, Z.; Shan, M.; Li, L.; Lu, L.; Meng, S.; Chen, C.; He, Y.; Jiang, S.; Zhang, L. in vitro selection and characterization of HIV-1 variants with increased resistance to sifuvirtide, a novel HIV-1 fusion inhibitor. J. Biol. Chem. 2011, 286, 3277-3287.
286. Shimura, K.; Nameki, D.; Kajiwara, K.; Watanabe, K.; Sakagami, Y.; Oishi, S.; Fujii, N.; Matsuoka, M.; Sarafianos, S.G.; Kodama, E.N. Resistance profiles of novel electrostatically constrained HIV-1 fusion inhibitors. J. Biol. Chem. 2010, 285, 39471-39480.
287. Izumi, K.; Kodama, E.; Shimura, K.; Sakagami, Y.; Watanabe, K.; Ito, S.; Watabe, T.; Terakawa, Y.; Nishikawa, H.; Sarafianos, S.G.; et al. Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20. J. Biol. Chem. 2009, 284, 4914-4920.
288. Dwyer, J.J.; Wilson, K.L.; Davison, D.K.; Freel, S.A.; Seedorff, J.E.; Wring, S.A.; Tvermoes, N.A.; Matthews, T.J.; Greenberg, M.L.; Delmedico, M.K. Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus. Proc. Natl. Acad. Sci. U. S. A. 2007, 104, 12772-12777.
289. Kahle, K.M.; Steger, H.K.; Root, M.J. Asymmetric deactivation of HIV-1 gp41 following fusion inhibitor binding. PLoS Pathog. 2009, 5, e1000674.
290. Gallo, S.A.; Sackett, K.; Rawat, S.S.; Shai, Y.; Blumenthal, R. The stability of the intact envelope glycoproteins is a major determinant of sensitivity of HIV/SIV to peptidic fusion inhibitors. J. Mol. Biol. 2004, 340, 9-14.
291. Eggink, D.; Bontjer, I.; Langedijk, J.P.; Berkhout, B.; Sanders, R.W. Resistance of human immunodeficiency virus type 1 to a third-generation fusion inhibitor requires multiple mutations in gp41 and is accompanied by a dramatic loss of gp41 function. J. Virol. 2011, 85, 10785-10797.
292. Ingallinella, P.; Bianchi, E.; Ladwa, N.A.; Wang, Y.J.; Hrin, R.; Veneziano, M.; Bonelli, F.; Ketas, T.J.; Moore, J.P.; Miller, M.D.; et al. Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency. Proc. Natl. Acad. Sci. U. S. A. 2009, 106, 5801-5806.
293. Hildinger, M.; Dittmar, M.T.; Schult-Dietrich, P.; Fehse, B.; Schnierle, B.S.; Thaler, S.; Stiegler, G.; Welker, R.; von Laer, D. Membrane-anchored peptide inhibits human immunodeficiency virus entry. J. Virol. 2001, 75, 3038-3042.
294. Egelhofer, M.; Brandenburg, G.; Martinius, H.; Schult-Dietrich, P.; Melikyan, G.; Kunert, R.; Baum, C.; Choi, I.; Alexandrov, A.; von Laer, D. Inhibition of human immunodeficiency virus type 1 entry in cells expressing gp41-derived peptides. J. Virol. 2004, 78, 568-575.
295. Peisajovich, S.G.; Gallo, S.A.; Blumenthal, R.; Shai, Y. C-terminal octylation rescues an inactive T20 mutant: Implications for the mechanism of HIV/SIMIAN immunodeficiency virus-induced membrane fusion. J. Biol. Chem. 2003, 278, 21012-21017.
296. Hermann, F.G.; Egerer, L.; Brauer, F.; Gerum, C.; Schwalbe, H.; Dietrich, U.; von Laer, D. Mutations in gp120 contribute to the resistance of human immunodeficiency virus type 1 to membrane-anchored C-peptide maC46. J. Virol. 2009, 83, 4844-4853.
297. Lohrengel, S.; Hermann, F.; Hagmann, I.; Oberwinkler, H.; Scrivano, L.; Hoffmann, C.; von Laer, D.; Dittmar, M.T. Determinants of human immunodeficiency virus type 1 resistance to membrane-anchored gp41-derived peptides. J. Virol. 2005, 79, 10237-10246.
298. Welch, B.D.; VanDemark, A.P.; Heroux, A.; Hill, C.P.; Kay, M.S. Potent D-peptide inhibitors of HIV-1 entry. Proc. Natl. Acad. Sci. U. S. A. 2007, 104, 16828-16833.
299. Derdeyn, C.A.; Decker, J.M.; Sfakianos, J.N.; Wu, X.; O'Brien, W.A.; Ratner, L.; Kappes, J.C.; Shaw, G.M.; Hunter, E. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J. Virol. 2000, 74, 8358-8367.
300. Reeves, J.D.; Miamidian, J.L.; Biscone, M.J.; Lee, F.H.; Ahmad, N.; Pierson, T.C.; Doms, R.W. Impact of mutations in the coreceptor binding site on human immunodeficiency virus type 1 fusion, infection, and entry inhibitor sensitivity. J. Virol. 2004, 78, 5476-5485.
301. Reeves, J.D.; Lee, F.H.; Miamidian, J.L.; Jabara, C.B.; Juntilla, M.M.; Doms, R.W. Enfuvirtide resistance mutations: Impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization. J. Virol. 2005, 79, 4991-4999.
302. Miyauchi, K.; Kozlov, M.M.; Melikyan, G.B. Early steps of HIV-1 fusion define the sensitivity to inhibitory peptides that block 6-helix bundle formation. PLoS Pathog. 2009, 5, e1000585.
303. Abrahamyan, L.G.; Mkrtchyan, S.R.; Binley, J.; Lu, M.; Melikyan, G.B.; Cohen, F.S. The cytoplasmic tail slows the folding of human immunodeficiency virus type 1 Env from a late prebundle configuration into the six-helix bundle. J. Virol. 2005, 79, 106-115.
304. Wild, C.; Dubay, J.W.; Greenwell, T.; Baird, T., Jr.; Oas, T.G.; McDanal, C.; Hunter, E.; Matthews, T. Propensity for a leucine zipper-like domain of human immunodeficiency virus type 1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex. Proc. Natl. Acad. Sci. U. S. A. 1994, 91, 12676-12680.
305. Lawless, M.K.; Barney, S.; Guthrie, K.I.; Bucy, T.B.; Petteway, S.R., Jr.; Merutka, G. HIV-1 membrane fusion mechanism: Structural studies of the interactions between biologically-active peptides from gp41. Biochemistry 1996, 35, 13697-13708.
306. Dwyer, J.J.; Hasan, A.; Wilson, K.L.; White, J.M.; Matthews, T.J.; Delmedico, M.K. The hydrophobic pocket contributes to the structural stability of the N-terminal coiled coil of HIV gp41 but is not required for six-helix bundle formation. Biochemistry 2003, 42, 4945-4953.
307. Blacklow, S.C.; Lu, M.; Kim, P.S. A trimeric subdomain of the simian immunodeficiency virus envelope glycoprotein. Biochemistry 1995, 34, 14955-14962.
308. Lu, M.; Kim, P.S. A trimeric structural subdomain of the HIV-1 transmembrane glycoprotein. J. Biomol. Struct. Dynam. 1997, 15, 465-471.
309. Eckert, D.M.; Kim, P.S. Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region. Proc. Natl. Acad. Sci. U. S. A. 2001, 98, 11187-11192.
310. Louis, J.M.; Bewley, C.A.; Clore, G.M. Design and properties of N(CCG)-gp41, a chimeric gp41 molecule with nanomolar HIV fusion inhibitory activity. J. Biol. Chem. 2001, 276, 29485-29489.
311. Louis, J.M.; Nesheiwat, I.; Chang, L.; Clore, G.M.; Bewley, C.A. Covalent trimers of the internal N-terminal trimeric coiled-coil of gp41 and antibodies directed against them are potent inhibitors of HIV envelope-mediated cell fusion. J. Biol. Chem. 2003, 278, 20278-20285.
312. Chen, X.; Lu, L.; Qi, Z.; Lu, H.; Wang, J.; Yu, X.; Chen, Y.; Jiang, S. Novel recombinant engineered gp41 N-terminal heptad repeat trimers and their potential as anti-HIV-1 therapeutics or microbicides. J. Biol. Chem. 2010, 285, 25506-25515.
313. Bianchi, E.; Finotto, M.; Ingallinella, P.; Hrin, R.; Carella, A.V.; Hou, X.S.; Schleif, W.A.; Miller, M.D.; Geleziunas, R.; Pessi, A. Covalent stabilization of coiled coils of the HIV gp41 N region yields extremely potent and broad inhibitors of viral infection. Proc. Natl. Acad. Sci. U. S. A. 2005, 102, 12903-12908.
314. Wexler-Cohen, Y.; Shai, Y. Membrane-anchored HIV-1 N-heptad repeat peptides are highly potent cell fusion inhibitors via an altered mode of action. PLoS Pathog. 2009, 5, e1000509.
315. Wexler-Cohen, Y.; Ashkenazi, A.; Viard, M.; Blumenthal, R.; Shai, Y. Virus-cell and cell-cell fusion mediated by the HIV-1 envelope glycoprotein is inhibited by short gp41 N-terminal membrane-anchored peptides lacking the critical pocket domain. FASEB J. 2010, 24, 4196-4202.
316. Root, M.J.; Kay, M.S.; Kim, P.S. Protein design of an HIV-1 entry inhibitor. Science 2001, 291, 884-888.
317. Bewley, C.A.; Louis, J.M.; Ghirlando, R.; Clore, G.M. Design of a novel peptide inhibitor of HIV fusion that disrupts the internal trimeric coiled-coil of gp41. J. Biol. Chem. 2002, 277, 14238-14245.
318. Desmezieres, E.; Gupta, N.; Vassell, R.; He, Y.; Peden, K.; Sirota, L.; Yang, Z.; Wingfield, P.; Weiss, C.D. Human immunodeficiency virus (HIV) gp41 escape mutants: Cross-resistance to peptide inhibitors of HIV fusion and altered receptor activation of gp120. J. Virol. 2005, 79, 4774-4781.
319. Wang, W.; de Feo, C.J.; Zhuang, M.; Vassell, R.; Weiss, C.D. Selection with a peptide fusion inhibitor corresponding to the first heptad repeat of HIV-1 gp41 identifies two genetic pathways conferring cross-resistance to peptide fusion inhibitors corresponding to the first and second heptad repeats (HR1 and HR2) of gp41. J. Virol. 2011, 85, 12929-12938.
320. Zhuang, M.; Wang, W.; de Feo, C.J.; Vassell, R.; Weiss, C.D. Trimeric, coiled-coil extension on peptide fusion inhibitor of HIV-1 influences selection of resistance pathways. J. Biol. Chem. 2012, 287, 8297-8309.
321. Izumi, K.; Nakamura, S.; Nakano, H.; Shimura, K.; Sakagami, Y.; Oishi, S.; Uchiyama, S.; Ohkubo, T.; Kobayashi, Y.; Fujii, N.; et al. Characterization of HIV-1 resistance to a fusion inhibitor, N36, derived from the gp41 amino-terminal heptad repeat. Antivir. Res. 2010, 87, 179-186.
322. Steger, H.K.; Root, M.J. Kinetic dependence to HIV-1 entry inhibition. J. Biol. Chem. 2006, 281, 25813-25821.
323. O'Brien, W.A.; Sumner-Smith, M.; Mao, S.H.; Sadeghi, S.; Zhao, J.Q.; Chen, I.S. Anti-human immunodeficiency virus type 1 activity of an oligocationic compound mediated via gp120 V3 interactions. J. Virol. 1996, 70, 2825-2831.
324. Pleskoff, O.; Sol, N.; Marrakchi, H.; Serlin, M.; Seman, M.; Alizon, M. Possible role of the V3 domain of gp120 in resistance to an amphotericin B derivative (MS8209) blocking human immunodeficiency virus entry. J. Virol. 1996, 70, 8247-8251.
325. Este, J.A.; Cabrera, C.; Schols, D.; Cherepanov, P.; Gutierrez, A.; Witvrouw, M.; Pannecouque, C.; Debyser, Z.; Rando, R.F.; Clotet, B.; et al. Human immunodeficiency virus glycoprotein gp120 as the primary target for the antiviral action of AR177 (Zintevir). Mol. Pharmacol. 1998, 53, 340-345.
326. Munch, J.; Standker, L.; Adermann, K.; Schulz, A.; Schindler, M.; Chinnadurai, R.; Pohlmann, S.; Chaipan, C.; Biet, T.; Peters, T.; et al. Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. Cell 2007, 129, 263-275.
327. Gonzalez-Ortega, E.; Ballana, E.; Badia, R.; Clotet, B.; Este, J.A. Compensatory mutations rescue the virus replicative capacity of VIRIP-resistant HIV-1. Antivir. Res. 2011, 92, 479-483.
328. Gonzalez, E.; Ballana, E.; Clotet, B.; Este, J.A. Development of resistance to VIR-353 with cross-resistance to the natural HIV-1 entry virus inhibitory peptide (VIRIP). AIDS 2011, 25, 1557-1583.
329. Mayaux, J.F.; Bousseau, A.; Pauwels, R.; Huet, T.; Henin, Y.; Dereu, N.; Evers, M.; Soler, F.; Poujade, C.; de Clercq, E.; et al. Triterpene derivatives that block entry of human immunodeficiency virus type 1 into cells. Proc. Natl. Acad. Sci. U. S. A. 1994, 91, 3564-3568.
330. Labrosse, B.; Treboute, C.; Alizon, M. Sensitivity to a nonpeptidic compound (RPR103611) blocking human immunodeficiency virus type 1 Env-mediated fusion depends on sequence and accessibility of the gp41 loop region. J. Virol. 2000, 74, 2142-2150.
331. Labrosse, B.; Pleskoff, O.; Sol, N.; Jones, C.; Henin, Y.; Alizon, M. Resistance to a drug blocking human immunodeficiency virus type 1 entry (RPR103611) is conferred by mutations in gp41. J. Virol. 1997, 71, 8230-8236.
332. Holz-Smith, S.L.; Sun, I.C.; Jin, L.; Matthews, T.J.; Lee, K.H.; Chen, C.H. Role of human immunodeficiency virus (HIV) type 1 envelope in the anti-HIV activity of the betulinic acid derivative IC9564. Antimicrob. Agents Chemother. 2001, 45, 60-66.
333. Yuan, X.; Huang, L.; Ho, P.; Labranche, C.; Chen, C.H. Conformation of gp120 determines the sensitivity of HIV-1 DH012 to the entry inhibitor IC9564. Virology 2004, 324, 525-530.
334. Lai, W.; Huang, L.; Ho, P.; Li, Z.; Montefiori, D.; Chen, C.H. Betulinic acid derivatives that target gp120 and inhibit multiple genetic subtypes of human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 2008, 52, 128-136.
335. Huang, L.; Lai, W.; Ho, P.; Chen, C.H. Induction of a nonproductive conformational change in gp120 by a small molecule HIV type 1 entry inhibitor. AIDS Res. Hum. Retrovir. 2007, 23, 28-32.
336. Murray, E.J.; Leaman, D.P.; Pawa, N.; Perkins, H.; Pickford, C.; Perros, M.; Zwick, M.B.; Butler, S.L. A low-molecular-weight entry inhibitor of both CCR5-and CXCR4-tropic strains of human immunodeficiency virus type 1 targets a novel site on gp41. J. Virol. 2010, 84, 7288-7299.
337. Schulz, T.F.; Jameson, B.A.; Lopalco, L.; Siccardi, A.G.; Weiss, R.A.; Moore, J.P. Conserved structural features in the interaction between retroviral surface and transmembrane glycoproteins? AIDS Res. Hum. Retrovir. 1992, 8, 1571-1580.
338. Cao, J.; Bergeron, L.; Helseth, E.; Thali, M.; Repke, H.; Sodroski, J. Effects of amino acid changes in the extracellular domain of the human immunodeficiency virus type 1 gp41 envelope glycoprotein. J. Virol. 1993, 67, 2747-2755.
339. Merat, R.; Raoul, H.; Leste-Lasserre, T.; Sonigo, P.; Pancino, G. Variable constraints on the principal immunodominant domain of the transmembrane glycoprotein of human immunodeficiency virus type 1. J. Virol. 1999, 73, 5698-5706.
340. Binley, J.M.; Sanders, R.W.; Clas, B.; Schuelke, N.; Master, A.; Guo, Y.; Kajumo, F.; Anselma, D.J.; Maddon, P.J.; Olson, W.C.; et al. A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure. J. Virol. 2000, 74, 627-643.
341. Maerz, A.L.; Drummer, H.E.; Wilson, K.A.; Poumbourios, P. Functional analysis of the disulfide-bonded loop/chain reversal region of human immunodeficiency virus type 1 gp41 reveals a critical role in gp120-gp41 association. J. Virol. 2001, 75, 6635-6644.
342. Jacobs, A.; Sen, J.; Rong, L.; Caffrey, M. Alanine scanning mutants of the HIV gp41 loop. J. Biol. Chem. 2005, 280, 27284-27288.
343. Sen, J.; Jacobs, A.; Jiang, H.; Rong, L.; Caffrey, M. The disulfide loop of gp41 is critical to the furin recognition site of HIV gp160. Protein Sci. 2007, 16, 1236-1241.
344. Kim, S.; Pang, H.B.; Kay, M.S. Peptide mimic of the HIV envelope gp120-gp41 interface. J. Mol. Biol. 2008, 376, 786-797.
345. Bellamy-McIntyre, A.K.; Bar, S.; Ludlow, L.; Drummer, H.E.; Poumbourios, P. Role for the disulfide-bonded region of human immunodeficiency virus type 1 gp41 in receptor-triggered activation of membrane fusion function. Biochem. Biophys. Res. Comm. 2010, 394, 904-908.
346. Finzi, A.; Xiang, S.H.; Pacheco, B.; Wang, L.; Haight, J.; Kassa, A.; Danek, B.; Pancera, M.; Kwong, P.D.; Sodroski, J. Topological layers in the HIV-1 gp120 inner domain regulate gp41 interaction and CD4-triggered conformational transitions. Mol. Cell 2010, 37, 656-667.
347. Platt, E.J.; Durnin, J.P.; Kabat, D. Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus. J. Virol. 2005, 79, 4347-4356.
348. Mkrtchyan, S.R.; Markosyan, R.M.; Eadon, M.T.; Moore, J.P.; Melikyan, G.B.; Cohen, F.S. Ternary complex formation of human immunodeficiency virus type 1 Env, CD4, and chemokine receptor captured as an intermediate of membrane fusion. J. Virol. 2005, 79, 11161-11169.
349. Abrahamyan, L.G.; Markosyan, R.M.; Moore, J.P.; Cohen, F.S.; Melikyan, G.B. Human immunodeficiency virus type 1 Env with an intersubunit disulfide bond engages coreceptors but requires bond reduction after engagement to induce fusion. J. Virol. 2003, 77, 5829-5836.
350. Haim, H.; Strack, B.; Kassa, A.; Madani, N.; Wang, L.; Courter, J.R.; Princiotto, A.; McGee, K.; Pacheco, B.; Seaman, M.S.; et al. Contribution of intrinsic reactivity of the HIV-1 envelope glycoproteins to CD4-independent infection and global inhibitor sensitivity. PLoS Pathog. 2011, 7, e1002101.
351. Xiang, S.H.; Finzi, A.; Pacheco, B.; Alexander, K.; Yuan, W.; Rizzuto, C.; Huang, C.C.; Kwong, P.D.; Sodroski, J. A V3 loop-dependent gp120 element disrupted by CD4 binding stabilizes the human immunodeficiency virus envelope glycoprotein trimer. J. Virol. 2010, 84, 3147-3161.
352. Mao, Y.; Wang, L.; Gu, C.; Herschhorn, A.; Xiang, S.H.; Haim, H.; Yang, X.; Sodroski, J. Subunit organization of the membrane-bound HIV-1 envelope glycoprotein trimer. Nat. Struct. Mol. Biol. 2012, 19, 893-899.